<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1111211303
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pexapan
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        APIXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        231.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AF02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pexapan&trade; contains the active substance apixaban and belongs to a group of<br />medicines called anticoagulants. This medicine helps to prevent blood clots<br />from forming by blocking Factor Xa, which is an important component of<br />blood clotting.<br />Pexapan&trade; is used in adults:<br />- to prevent blood clots (deep vein thrombosis [DVT]) from forming after hip<br />or knee replacement operations. After an operation to the hip or knee you<br />may be at a higher risk of developing blood clots in your leg veins. This can<br />cause the legs to swell, with or without pain. If a blood clot travels from your<br />leg to your lungs, it can block blood flow causing breathlessness, with or<br />without chest pain. This condition (pulmonary embolism) can be<br />life-threatening and requires immediate medical attention.<br />- to prevent a blood clot from forming in the heart in patients with an<br />irregular heart beat (atrial fibrillation) and at least one additional risk factor.<br />Blood clots may break off and travel to the brain and lead to a stroke or to<br />other organs and prevent normal blood flow to that organ (also known as a<br />systemic embolism). A stroke can be life-threatening and requires immediate<br />medical attention.<br />- to treat blood clots in the veins of your legs (deep vein thrombosis) and in<br />the blood vessels of your lungs (pulmonary embolism), and to prevent blood<br />clots from re-occurring in the blood vessels of your legs and/or lungs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Pexapan&trade; if:<br />- you are allergic to apixaban or any of the other ingredients of this<br />medicine (listed in section 6)<br />- you are bleeding excessively<br />- you have a disease in an organ of the body that increases the risk of<br />serious bleeding (such as an active or a recent ulcer of your stomach or<br />bowel, recent bleeding in your brain)<br />- you have a liver disease which leads to increased risk of bleeding<br />(hepatic coagulopathy)<br />- you are taking medicines to prevent blood clotting (e.g., warfarin,<br />rivaroxaban, dabigatran or heparin), except when changing anticoagulant<br />treatment, while having a venous or arterial line and you get heparin through<br />this line to keep it open, or if a tube is inserted into your blood vessel<br />(catheter ablation) to treat an irregular heartbeat (arrhythmia).<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before you take this medicine if you<br />have any of the following:<br />- an increased risk of bleeding, such as:<br />&bull; bleeding disorders, including conditions resulting in reduced platelet<br />activity<br />&bull; very high blood pressure, not controlled by medical treatment<br />&bull; you are older than 75 years<br />&bull; you weigh 60 kg or less<br />- a severe kidney disease or if you are on dialysis<br />- a liver problem or a history of liver problems<br />Pexapan&trade; will be used with caution in patients with signs of altered liver<br />function.<br />- had a tube (catheter) or an injection into your spinal column<br />(for anaesthesia or pain reduction), your doctor will tell you to take<br />Pexapan&trade; 5 hours or more after catheter removal.<br />- if you have a prosthetic heart valve<br />- if your doctor determines that your blood pressure is unstable or another<br />treatment or surgical procedure to remove the blood clot from your lungs is<br />planned<br />Take special care with Pexapan&trade;<br />- if you know that you have a disease called antiphospholipid syndrome (a<br />disorder of the immune system that causes an increased risk of blood clots),<br />tell your doctor who will decide if the treatment may need to be changed.<br />If you need to have surgery or a procedure which may cause bleeding, your<br />doctor might ask you to temporarily stop taking this medicine for a short<br />while. If you are not sure whether a procedure may cause bleeding ask your<br />doctor.<br />Children and adolescents<br />Pexapan&trade; is not recommended in children and adolescents under 18 years<br />of age.<br />Other medicines and Pexapan&trade;<br />Tell your doctor, pharmacist or nurse if you are taking, have recently taken<br />or might take any other medicines.<br />Some medicines may increase the effects of Pexapan&trade; and some may<br />decrease its effects. Your doctor will decide, if you should be treated with<br />Pexapan&trade; when taking these medicines and how closely you should be<br />monitored.<br />The following medicines may increase the effects of Pexapan&trade; and increase<br />the chance for unwanted bleeding:<br />- some medicines for fungal infections (e.g., ketoconazole, etc.)<br />- some antiviral medicines for HIV / AIDS (e.g., ritonavir)<br />- other medicines that are used to reduce blood clotting<br />(e.g., enoxaparin, etc.)<br />- anti-inflammatory or pain medicines (e.g., acetylsalicylic acid or<br />naproxen). Especially, if you are older than 75 years and are taking<br />acetylsalicylic acid, you may have an increased chance of bleeding.<br />- medicines for high blood pressure or heart problems (e.g., diltiazem) 2<br />- antidepressant medicines called selective serotonin re-uptake inhibitors<br />or serotonin norepinephrine re-uptake inhibitors.<br />The following medicines may reduce the ability of Pexapan&trade; to help<br />prevent blood clots from forming:<br />- medicines to prevent epilepsy or seizures (e.g., phenytoin, etc.)<br />- St John&rsquo;s Wort (a herbal supplement used for depression)<br />- medicines to treat tuberculosis or other infections (e.g., rifampicin)<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor, pharmacist or nurse for advice<br />before taking this medicine.<br />The effects of Pexapan&trade; on pregnancy and the unborn child are not known.<br />You should not take Pexapan&trade; if you are pregnant. Contact your doctor<br />immediately if you become pregnant while taking Pexapan&trade;.<br />It is not known if Pexapan&trade; passes into human breast milk. Ask your<br />doctor, pharmacist or nurse for advice before taking this medicine while<br />breast-feeding. They will advise you to either stop breast- feeding or to<br />stop/not start taking Pexapan&trade;.<br />Driving and using machines<br />Pexapan&trade; has not been shown to impair your ability to drive or use<br />machines.<br />Pexapan&trade; contains lactose (a type of sugar) and sodium<br />If you have been told by your doctor that you have an intolerance to some<br />sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you.<br />Check with your doctor, pharmacist or nurse if you are not sure.<br />Dose<br />Swallow the tablet with a drink of water. Pexapan&trade; can be taken with or<br />without food. Try to take the tablets at the same times every day to have the<br />best treatment effect.<br />If you have difficulty swallowing the tablet whole, talk to your doctor about<br />other ways to take Pexapan&trade;. The tablet may be crushed and mixed with<br />water, or 5% dextrose in water, or apple juice or apple puree, immediately<br />before you take it.<br />Instructions for crushing:<br />&bull; Crush the tablets with a pestle and mortar.<br />&bull; Transfer all the powder carefully into a suitable container then mix the<br />powder with a little e.g., 30 mL (2 tablespoons), water or one of the other<br />liquids mentioned above to make a mixture.<br />&bull; Swallow the mixture.<br />&bull; Rinse the pestle and mortar you used for crushing the tablet and the<br />container, with a little water or one of the other liquids (e.g., 30 mL), and<br />swallow the rinse.<br />If necessary, your doctor may also give you the crushed Pexapan&trade; tablet<br />mixed in 60 mL of water or 5% dextrose in water, through a nasogastric<br />tube.<br />Take Pexapan&trade; as recommended for the following:<br />To prevent blood clots from forming after hip or knee replacement<br />operations.<br />The recommended dose is one tablet of Pexapan&trade; 2.5 mg twice a day.<br />For example, one in the morning and one in the evening.<br />You should take the first tablet 12 to 24 hours after your operation.<br />If you have had a major hip operation you will usually take the tablets<br />for 32 to 38 days<br />If you have had a major knee operation you will usually take the tablets<br />for 10 to 14 days<br />To prevent a blood clot from forming in the heart in patients with an<br />irregular heart beat and at least one additional risk factor.<br />The recommended dose is one tablet of Pexapan&trade; 5 mg twice a day.<br />The recommended dose is one tablet of Pexapan&trade; 2.5 mg twice a day if:<br />- you have severely reduced kidney function<br />- two or more of the following apply to you:<br />&bull; your blood test results suggest poor kidney function (value of serum<br />creatinine is 1.5 mg/dL (133 micromole/L) or greater)<br />&bull; you are 80 years old or older<br />&bull; your weight is 60 kg or lower.<br />The recommended dose is one tablet twice a day, for example, one in the<br />morning and one in the evening. Your doctor will decide how long you must<br />continue treatment for.<br />To treat blood clots in the veins of your legs and blood clots in the blood<br />vessels of your lungs<br />The recommended dose is two tablets of Pexapan&trade; 5 mg twice a day for the<br />first 7 days, for example, two in the morning and two in the evening.<br />After 7 days the recommended dose is one tablet of Pexapan&trade; 5 mg twice a<br />day, for example, one in the morning and one in the evening.<br />For preventing blood clots from re-occurring following completion of 6<br />months of treatment<br />The recommended dose is one tablet of Pexapan&trade; 2.5 mg twice a day for<br />example, one in the morning and one in the evening.<br />Your doctor will decide how long you must continue treatment for.<br />Your doctor might change your anticoagulant treatment as follows:<br />- Changing from Pexapan&trade; to anticoagulant medicines<br />Stop taking Pexapan&trade;. Start treatment with the anticoagulant medicines<br />(for example heparin) at the time you would have taken the next tablet.<br />- Changing from anticoagulant medicines to Pexapan&trade;<br />Stop taking the anticoagulant medicines. Start treatment with Pexapan&trade; at<br />the time you would have had the next dose of anticoagulant medicine, then<br />continue as normal.<br />- Changing from treatment with anticoagulant containing vitamin K<br />antagonist (e.g., warfarin) to Pexapan&trade;<br />Stop taking the medicine containing a vitamin K antagonist. Your doctor<br />needs to do blood-measurements and instruct you when to start taking<br />Pexapan&trade;.<br />- Changing from Pexapan&trade; to anticoagulant treatment containing<br />vitamin K antagonist (e.g., warfarin).<br />If your doctor tells you that you have to start taking the medicine containing<br />a vitamin K antagonist, continue to take Pexapan&trade; for at least 2 days after<br />your first dose of the medicine containing a vitamin K antagonist. Your<br />doctor needs to do blood-measurements and instruct you when to stop taking<br />Pexapan&trade;.</p><p>Patients undergoing cardioversion<br />If your abnormal heartbeat needs to be restored to normal by a<br />procedure called cardioversion, take Pexapan&trade; at the times your doctor<br />tells you, to prevent blood clots in blood vessels in your brain and other<br />blood vessels in your body.<br />If you take more Pexapan&trade; than you should<br />Tell your doctor immediately if you have taken more than the<br />prescribed dose of Pexapan&trade;. Take the medicine pack with you, even if<br />there are no tablets left.<br />If you take more Pexapan&trade; than recommended, you may have an<br />increased risk of bleeding. If bleeding occurs, surgery, blood<br />transfusions, or other treatments that may reverse anti-factor Xa activity<br />may be required.<br />If you forget to take Pexapan&trade;<br />- Take the dose as soon as you remember and:<br />- take the next dose of Pexapan&trade; at the usual time<br />- then continue as normal.<br />If you are not sure what to do or have missed more than one dose,<br />ask your doctor, pharmacist or nurse.<br />If you stop taking Pexapan&trade;<br />Do not stop taking Pexapan&trade; without talking to your doctor first,<br />because the risk of developing a blood clot could be higher if you stop<br />treatment too early.<br />If you have any further questions on the use of this medicine, ask your<br />doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them. Pexapan&trade; can be given for three different<br />medical conditions. The known side effects and how frequently they<br />occur for each of these medical conditions may differ and are listed<br />separately below.For these conditions, the most common general side<br />effect of Pexapan&trade; is bleeding which may be potentially life<br />threatening and require immediate medical attention.<br />The following side effects are known if you take Pexapan&trade; to prevent<br />blood clots from forming after hip or knee replacement operations.<br />Common side effects (may affect up to 1 in 10 people)<br />- Anaemia which may cause tiredness or paleness<br />- Bleeding including: &bull; bruising and swelling<br />- Nausea (feeling sick)<br />Uncommon side effects (may affect up to 1 in 100 people)<br />- Reduced number of platelets in your blood (which can affect clotting)<br />- Bleeding:<br />&bull; occurring after your operation including bruising and swelling, blood<br />or liquid leaking from the surgical wound/incision (wound secretion) or<br />injection site<br />&bull; in your stomach, bowel or bright/red blood in the stools<br />&bull; blood in the urine &bull; from your nose &bull; from the vagina<br />&bull; Low blood pressure which may make you feel faint or have a<br />quickened heartbeat<br />- Blood tests may show:<br />&bull; abnormal liver function &bull; an increase in some liver enzymes<br />&bull; an increase in bilirubin, a breakdown product of red blood cells, which<br />can cause yellowing of the skin and eyes.<br />- Itching<br />Rare side effects (may affect up to 1 in 1,000 people)<br />- Allergic reactions (hypersensitivity) which may cause: swelling of the<br />face, lips, mouth, tongue and/or throat and difficulty breathing. Contact<br />your doctor immediately if you experience any of these symptoms.<br />- Bleeding: &bull; into a muscle &bull; in your eyes<br />&bull; from your gums and blood in your spit when coughing<br />&bull; from your rectum<br />- Hair loss<br />Not known (frequency cannot be estimated from the available data)<br />- Bleeding:<br />&bull; in your brain or in your spinal column,<br />&bull; in your lungs or your throat &bull; in your mouth<br />&bull; into your abdomen or space behind your abdominal cavity<br />&bull; from a haemorrhoid<br />&bull; tests showing blood in the stools or in the urine<br />- Skin rash<br />The following side effects are known if you take Pexapan&trade; to prevent a<br />blood clot from forming in the heart in patients with an irregular heart<br />beat and at least one additional risk factor.<br />Common side effects (may affect up to 1 in 10 people)<br />- Bleeding including: &bull; in your eyes &bull; in your stomach or bowel<br />&bull; from your rectum &bull; blood in the urine &bull; from your nose<br />&bull; from your gums &bull; bruising and swelling<br />- Anaemia which may cause tiredness or paleness<br />- Low blood pressure which may make you feel faint or have a<br />quickened heartbeat - Nausea (feeling sick)<br />- Blood tests may show:<br />&bull; an increase in gamma-glutamyltransferase (GGT)<br />Uncommon side effects (may affect up to 1 in 100 people)<br />- Bleeding:<br />&bull; in your brain or in your spinal column<br />&bull; in your mouth or blood in your spit when coughing<br />&bull; into your abdomen, or from the vagina<br />&bull; bright/red blood in the stools<br />&bull; bleeding occurring after any operation including bruising and swelling,<br />blood or liquid leaking from the surgical wound/incision (wound<br />secretion) or injection site - from a haemorrhoid<br />&bull; tests showing blood in the stools or in the urine<br />- Reduced number of platelets in your blood (which can affect clotting)<br />- Blood tests may show:<br />&bull; abnormal liver function<br />&bull; an increase in some liver enzymes<br />&bull; an increase in bilirubin, a breakdown product of red blood cells, which<br />can cause yellowing of the skin and eyes<br />- Skin rash - Itching - Hair loss<br />- Allergic reactions (hypersensitivity) which may cause: swelling of the<br />face, lips, mouth, tongue and/or throat and difficulty breathing. Contact<br />your doctor immediately if you experience any of these symptoms.<br />Rare side effects (may affect up to 1 in 1,000 people)<br />- Bleeding: &bull; in your lungs or your throat<br />&bull; into the space behind your abdominal cavity &bull; into a muscle<br />The following side effects are known if you take Pexapan&trade; to treat or<br />prevent re-occurrence of blood clots in the veins of your legs and blood<br />clots in the blood vessels of your lungs.<br />Common side effects (may affect up to 1 in 10 people)<br />- Bleeding including: &bull; from your nose &bull; from your gums<br />&bull; blood in the urine &bull; bruising and swelling<br />&bull; in your stomach, your bowel, from your rectum &bull; in your mouth<br />&bull; from the vagina<br />- Anaemia which may cause tiredness or paleness<br />- Reduced number of platelets in your blood (which can affect clotting)<br />- Nausea (feeling sick) - Skin rash<br />- Blood tests may show:<br />&bull; an increase in gamma-glutamyltransferase (GGT) or alanine<br />aminotransferase (ALT)<br />Uncommon side effects (may affect up to 1 in 100 people)<br />- Low blood pressure which may make you feel faint or have a<br />quickened heartbeat<br />- Bleeding: &bull; in your eyes &bull; in your mouth or blood in your spit when<br />coughing &bull; bright/red blood in the stools<br />&bull; tests showing blood in the stools or in the urine<br />&bull; bleeding occurring after your operation including bruising and<br />swelling, blood or liquid leaking from the surgical wound/incision<br />(wound secretion) or injection site - from a haemorrhoid<br />&bull; into a muscle<br />- Itching<br />- Hair loss<br />- Allergic reactions (hypersensitivity) which may cause: swelling of the<br />face, lips, mouth, tongue and/or throat and difficulty breathing. Contact<br />your doctor immediately if you experience any of these symptoms.<br />- Blood tests may show: &bull; abnormal liver function &bull; an increase in some<br />liver enzymes &bull; an increase in bilirubin, a breakdown product of red<br />blood cells, which can cause yellowing of the skin and eyes.<br />Rare side effects (may affect up to 1 in 1,000 people)<br />Bleeding:<br />&bull; in your brain or in your spinal column &bull; in your lungs<br />Not known (frequency cannot be estimated from the available data)<br />Bleeding:<br />&bull; into your abdomen or the space behind your abdominal cavity<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist, or nurse.<br />This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of reach and sight of children.<br />Do not store above 30 &ordm;C.<br />Do not use this medicine after the expiry date stated on the carton box<br />and blister after EXP.<br />Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Pexapan&trade; contains<br />&bull; The active substance is apixaban.<br />Pexapan&trade; 2.5 mg each film coated tablet contains 2.5 mg of apixaban.<br />Pexapan&trade; 5 mg each film coated tablet contains 5 mg of apixaban.<br />&bull; The other ingredients are:<br />Core: Lactose Anhydrous, Microcrystalline Cellulose, Croscarmellose<br />Sodium, Sodium Lauryl Sulfate, Magnesium Stearate.<br />Coating: Hydroxy propyl methyl Cellulose, Lactose Monohydrate,<br />Titanium Dioxide, Triacetin and Red Iron Oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Pexapan™ looks like and contents of the pack
Pexapan™ 2.5 mg tablets are pink, Round film coated tablets debossed
with ‘’BB’’ on one side and ‘’JP’’ on other side.
Pexapan™ 5 mg tablets are pink, oval film coated tablets debossed with
‘’BC’’ on one side and ‘’JP’’ on other side.
Pexapan™ 2.5 mg film coated tablets are available in a box of
20 tablets and 60 tablets.
Pexapan™ 5 mg film coated tablets are available in a box of 60 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111. Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02-09-2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>على المادة الفعّالة أبیكسابان وینتمي إلى مجموعة من الأدویة تُسمى &trade; یحتوي عقار بیكسابان<br />مضادات تجلط (مضادات تخثر الدم). یُساعد ھذا الدواء على منع تكوُّن الجلطات الدمویة عن<br />وھو عنصر ھام من عناصر تجلُّط الدَّم. ،(Xa) طریق وقف نشاط العامل العاشر<br />مع البالغین: &trade; یُستخدَم عقار بیكسابان<br />بعد إجراء جراحات (&quot;DVT&quot; - لمنع تكوُّن الجلطات الدمویة (التخثُّر الوریدي العمیق<br />استبدال مفصل الحوض أو الركبة. قد تكون أكثر عرضة لخطر الإصابة بجلطات دمویة في<br />أوردة الساق بعد إجراء جراحة بمفصل الحوض أو الركبة. یمكن أن یُسبب ذلك تورم بالساقین<br />مع الشعور بألم أو بدون الشعور بألم. إذا انتقل التجلط الدموي من الساق إلى الرئة، فقد یمنع<br />ذلك تدفق الدم مما یسبب ضیق التنفس مع الشعور بالألم أو بدون ألم. قد تكون ھذه الحالة التي<br />تُعرف بالانصمام الرئوي &quot;انسداد الشریان الرئوي&quot; مُھدِدة للحیاة وتستدعي العنایة الطبیة<br />الفوریة.<br />- لعلاج الجلطات الدمویة في أوردة الساق (التخثُّر الوریدي العمیق) وفي الأوعیة الدمویة<br />بالرئة (الانصمام الرئوي)، ولمنع تكرار حدوث الإصابة بالجلطات الدمویة في الأوعیة<br />الدمویة بالساق و/أو بالرئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول عقار بیكسابان<br />- كنت تُعاني من حساسیة تجاه مادة أبیكسابان أو أي مكون من المكونات الأخرى الداخلة في<br />.( تركیب ھذا الدَّواء (المدرجة في القسم رقم ٦<br />- كنت تُعاني من النزیف بشكل مفرط.<br />- كنت تُعاني من مرض بأحد أعضاء الجسم یُؤدي إلى ارتفاع نسبة خطورة حدوث نزیف<br />حاد (مثل قرحة نشطة أو حدیثة في المعدة أو الأمعاء أو نزیف في المخ أُصِبت بھ مؤخرًا).<br />- كنت تُعاني من مرض بالكبد یُؤدي إلى ارتفاع نسبة خطورة الإصابة بنزیف (تجلط الدَّم<br />الكبدي).<br />- كنت تتناول أدویة لمنع تجلط الدم (على سبیل المثال؛ وارفارین، ریفاروكسابان،<br />دابیجاتران أو ھیبارین)، ما عدا في حالة تغییر العلاج المضاد للتجلط أو عندما یكون مثبت<br />لك قسطرة رقیقة داخل مجري وریدي أو شریاني ویتم إعطاؤك ھیبارین من خلالھا لإبقائھ<br />مفتوحًا أو یتم إدخالھ في الأوعیة الدمویة (استئصال بالقسطرة) لعلاج عدم انتظام ضربات<br />القلب.<br />تحذیرات واحتیاطات<br />تحدث إلى طبیبك أو الصیدلي أو الممرض (ة) المتابع (ة) لحالتك قبل تناوُل ھذا الدواء، إذا<br />كان لدیك أى من الحالات التالیة:<br />- خطورة متزایدة لحدوث نزیف، وتشمل ما یلي:<br />&bull; اضطرابات نزفیة، بما في ذلك الحالات التي تُؤدي إلى انخفاض نشاط الصفائح الدَّمویة.<br />&bull; ارتفاع ضغط الدَّم الشدید، الذي لا یمكن التَّحكم بھ من خلال العلاج الطبي.<br />&bull; عمرك یتجاوز ۷٥ عامًا.<br />&bull; وزنك ٦۰ كجم أو أقل.<br />- مرض حاد بالكُلى أو إذا كنت تخضع للغسیل الكلوي.<br />- مشكلة بالكبد أو لدیك تاریخ مرضي من مشاكل الكبد.<br />بحذر مع المرضى الذین یعانون من علامات تغیُّر وظائف الكبد. &trade; یُستخدَم عقار بیكسابان<br />- إذا كان لدیك أنبوب مثبت (قسطرة) أو خضعت لحقن في العمود الفقري (للتخدیر أو<br />بعد ٥ ساعات أو أكثر من إزالة &trade; لتخفیف الألم)، فسیخبرك طبیبك بتناوُل عقار بیكسابان<br />القسطرة.<br />- إذا كنت قد خضعت لعملیة زراعة صمام اصطناعي داخل القلب.<br />- إذا أقر طبیبك بأن ضغط الدم غیر مستقر أو أنھ من المخطط تلقي علاج أو إجراء جراحي<br />آخر لإزالة الجلطة الدمویة من الرئة.<br />: &trade; صا مع عقار بیكسابان 􀌒 توخ حذرًا خا<br />- إذا كنت تعلم بأنك تعاني من مرض یسمى متلازمة الأجسام المضادة للشحوم الفسفوریة<br />(اضطراب في الجھاز المناعي یسبب زیادة خطر الإصابة بتجلط الدم)، أخبر طبیبك الذي<br />سیقرر ما إذا كان یتطلب تغییر العلاج أم لا.<br />إذا احتجت إلى الخضوع إلى جراحة أو أي إجراء قد یسبب لك نزیفًا، فقد یطلب طبیبك<br />التوقف مؤقتًا عن تناوُل ھذا الدواء لفترة قصیرة. استشر طبیبك ، إذا لم تكن متأكدًا مما إذا<br />كان الإجراء قد یُسبب نزیفًا أم لا.<br />الأطفال والمراھقین<br />في الأطفال والمراھقین الذین تقل أعمارھم عن ۱۸ &trade; لا یُوصى باستخدام عقار بیكسابان<br />عامًا.<br />مع الأدویة الأخرى: &trade; استخدام عقار بیكسابان<br />یُرجى إبلاغ طبیبك أو الصیدلي أو الممرض(ة) المتابعة(ة) لحالتك، إذا كنت تتناول أو تناولت<br />مؤخرًا أو قد تتناول أیَّة أدویة أخرى.<br />وقد تقلل بعض الأدویة من تأثیره. سیقرر &trade; قد تزید بعض الأدویة من تأثیرعقار بیكسابان<br />أثناء تناوُل ھذه الأدویة أم لا وإلى أي مدى &trade; طبیبك ما إذا كان یجب علاجك بعقار بیكسابان<br />یجب متابعة حالتك.<br />وزیادة نسبة حدوث نزیف وسیولة للدم &trade; الأدویة التَّالیة قد تزید من تأثیرات عقار بیكسابان<br />غیر مطلوبة:<br />- بعض الأدویة التي تستخدم لعلاج حالات العدوى الفطریة (مثل كیتوكونازول ، وما إلى<br />غیر ذلك).<br />- بعض الأدویة المضادة للفیروسات مثل أدویة علاج فیروس نقص المناعة<br />المكتسب/فیروس نقص المناعة البشریة (مثل ریتونافیر).<br />- بعض الأدویة التي تُستخدَم للحد من تجلط الدَّم (مثل إنُوكسابارین وما إلى غیر ذلك).<br />- الأدویة المضادة للالتھابات أو الألم (مثل حمض أسیتیل سالیسیلیك أو نابْروكْسین). وعلى<br />وجھ الخصوص، إذا كان عمرك یتجاوز ۷٥ عامًا وتتناول حمض أسیتیل سالیسیلیك، فقد<br />یؤدي ذلك إلى ارتفاع نسبة حدوث نزیف.<br />- الأدویة التي تستخدم لعلاج ارتفاع ضغط الدَّم أو مشاكل القلب (مثل دیلتیازیم).<br />- الأدویة المضادة للاكتئاب التي تُعرف باسم مثبطات إعادة امتصاص السیروتونین<br />أو مثبطات إعادة امتصاص السیروتونین والنورابنفرین. (SSRIs) الانتقائیة<br />على المساعدة في منع تكوُّن جلطات &trade; قد تقلل الأدویة التَّالیة من فعالیة عقار بیكسابان<br />دمویة:<br />- الأدویة التي تمنع حدوث نوبات صرع أو نوبات تشنجیة (مثل فینیتوین وما إلى غیر ذلك).<br />- نبتة سانت جونز (دواء عشبي یُستخدَم لعلاج الاكتئاب).<br />- الأدویة التي تعالج السل أو أنواع العدوى الأخرى (مثل ریفامبیسین).<br />الحمل والرضاعة الطبیعیة<br />إذا كنتِ حاملًا أو تمارسین الرضاعة الطبیعیة أو تعتقدین أنكِ حاملاً أو تخططین للحمل،<br />فاستشیري طبیبك أو الصیدليِ أو الممرض (ة) المتابع (ة) لحالتك قبل تناوُل ھذا الدَّواء.<br />على الحمل والجنین غیر معروفة. یحظر علیك تناول عقار &trade; حیث أن آثارعقار بیكسابان<br />إذا كنتِ حاملاً. اتصلي بطبیبك على الفور، إذا أصبحتِ حاملًا أثناء تناوُل عقار ،&trade; بیكسابان<br />.&trade; بیكسابان<br />یُفرز في لبن الأم أم لا. استشیري طبیبك أو &trade; من غیر المعروف ما إذا كان عقار بیكسابان<br />الصیدليِ أو الممرض (ة) المتابع (ة) لحالتكِ قبل تناوُل ھذا الدَّواء أثناء الرضاعة الطبیعیة.<br />حیث أنھم سوف یقدمون لكِ النصیحة إما بإیقاف الرضاعة الطبیعیة أو التَّوقف عن تناوُل<br />أو عدم البدء في تناولھ. &trade; عقار بیكسابان<br />القیادة واستخدام الآلات<br />آثار من شأنھا أن تضعف قدرتك على القیادة واستخدام الآلات. &trade; لم یُظھر عقار بیكسابان<br />على اللاكتوز (أحد أنواع السكر) والصودیوم. &trade; یحتوي عقار بیكسابان<br />إذا كان طبیبك قد أخبرك بأنك لا تتحمل بعض أنواع السكریات، فاتصل بھ قبل تناول ھذا<br />الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدَّواء تمامًا كما أخبرك طبیبك أو الصیدلي. یُرجى مراجعة طبیبك أو<br />الصیدلي أو الممرض (ة) المتابع (ة) لحالتك إذا لم تكن متأكدًا من كیفیة التَّناوُل.<br />الجرعة<br />مع الطعام أو بدونھ. حاول أن &trade; ابتلع القرص بكوب من الماء. یمكن تناوُل عقار بیكسابان<br />تتناول الأقراص في نفس الوقت من كل یوم للحصول على أفضل فعّالیة علاجیة.<br />إذا كنت تواجھ صعوبة في ابتلاع القرص كاملًا، فتحدث إلى طبیبك بشأن الطرق الأخرى<br />یمكن أن یتم تفتیت القرص وخلطھ مع الماء أو مع محلول .&trade; لتناول عقار بیكسابان<br />دكستروز ٥٪ في الماء أو مع عصیر التفاح أو ھریس التفاح مباشرًة قبل تناولھ.<br />تعلیمات تفتیت القرص:<br />&bull; قم بتكسیر القرص وتفتیھ باستخدام ھاوَنٌ ومِدَقَّ.<br />&bull; قم بنقل المسحوق كاملًا بعنایة في إناء مناسب، ثم اخلط المسحوق، على سبیل المثال، بقلیل<br />من الماء ۳۰ مل (ملعقتان كبیرتان) أو أحد السوائل الأخرى المذكورة أعلاه لتحضیر الخلیط.<br />&bull; ثم قم بابتلاع الخلیط.<br />&bull; قم بشطف الھَاون والمدق المستخدمین في سحق القرص إلى جانب الإناء المستخدم أیضًا<br />بالقلیل من الماء أو بأي من السوائل الأخرى (على سبیل المثال ۳۰ مل من الماء) ثم قم<br />بابتلاع السائل الناتج عن الشطف.<br />مطحونًا ومخلوطًا في &trade; إذا لزم الأمر، قد یقوم طبیبك بإعطائك قرص من عقار بیكسابان<br />٦۰ مل من المیاه أو مع محلول دكستروز ٥٪ في الماء، بواسطة أنبوب أنفي مِعدي.<br />على النحو الموصى بھ في الحالات التالیة: &trade; تناول عقار بیكسابان<br />بعد إجراء جراحات استبدال (&quot;DVT&quot; لمنع تكوُّن الجلطات الدمویة (التخثُّر الوریدي العمیق<br />مفصل الحوض أو الركبة.<br />۲٫٥ ملجم مرتین في الیوم. &trade; الجرعة الموصى بھا ھي قرص واحد من بیكسابان<br />على سبیل المثال ، قرص في الصباح و قرص في المساء.<br />یجب أن تأخذ أول قرص بعد ۱۲ إلى ۲٤ ساعة من إجراء العملیة.<br />إذا كنت قد خضعت لعملیة كبیرة في الحوض ، فعادة ما تتناول الأقراص لمدة ۳۲ إلى ۳۸<br />یومًا<br />إذا كنت قد خضعت لعملیة جراحیة كبیرة في الركبة ، فعادة ما تتناول الأقراص لمدة ۱۰ إلى<br />۱٤ یومًا.<br />لمنع تكوُّن الجلطات الدمویة في القلب لدي المرضى الذین یُعانون من عدم انتظام ضربات<br />القلب ووجود عامل خطر إضافي واحد على الأقل.<br />٥ ملجم مرتین یومیًا. &trade; الجرعة الموصى بھا ھي قرص واحد من عقار بیكسابان<br />۲٫٥ ملجم مرتین یومیًا. &trade; الجرعة الموصى بھا ھي قرص واحد من عقار بیكسابان<br />- إذا كنت تعاني من ضعف بوظائف الكُلى<br />- إذا كان ینطبق علیك حالتین أو أكثر من الحالات التالیة:<br />&bull; تشیر نتائج اختبار الدَّم الخاص بك إلى وجود ضعف بوظائف الكُلى (مستوى الكریاتینین<br />بالدَّم ھو ۱٫٥ ملجم/ دیسیلتر [ ۱۳۳ میكرو مول/ لتر] أو أكثر)<br />&bull; إذا كنت تبلغ من العمر ۸۰ سنة أو أكثر.<br />&bull; إذا كان وزنك ٦۰ كجم أو أقل.<br />الجرعة الموصى بھا ھي قرص واحد مرتین یومیًا، على سبیل المثال، قرص في الصباح<br />وآخر في المساء. سیقرر طبیبك المدة اللازمة للاستمرار في تلقي العلاج.<br />في حالة الاستخدام لعلاج الجلطات الدمویة في أوردة الساق والجلطات الدمویة في الأوعیة<br />الدمویة بالرئة.<br />مرتین یومیًا لفترة العلاج الأولى &trade; الجرعة الموصى بھا ھي قرصان من عقار بیكسابان<br />ومدتھا ۷ أیام، على سبیل المثال، قرصان في الصباح وقرصان في المساء.<br />بعد مرور ۷ أیام تكون الجرعة الموصى بھا ھي قرص واحد مرتین یومیًا من عقار بیكسابان<br />على سبیل المثال, قرص في الصباح وآخر في المساء. ,&trade;<br />في حالة الاستخدام لمنع تكرار حدوث جلطات دمویة بعد إتمام ستة أشھر من العلاج<br />مرتین یومیًا، على سبیل المثال &trade; الجرعة الموصى بھا ھي قرص واحد من عقار بیكسابان<br />قرص واحد في الصباح وآخر في المساء.<br />سیقرر طبیبك المدة اللازمة للاستمرار في تلقي العلاج.<br />قد یقوم طبیبك بتغییر العلاج المضاد للتجلط الخاص بك على النحو التَّالي:<br />إلى أدویة أخرى مضادة للتجلط &trade; - تغییر العلاج بعقار بیكسابان<br />ابدأ في العلاج بالأدویة المضادة للتجلط (مثل ھیبارین) .&trade; توقف عن تناوُل عقار بیكسابان<br />في الموعد المحدد لتناوُل القرص التالي.<br />:&trade; - تغییر العلاج بالأدویة الأخرى المضادة للتجلط إلى عقار بیكسابان<br />في وقت تناوُل &trade; توقف عن تناوُل الأدویة المضادة للتجلط، ابدأ العلاج بعقار بیكسابان<br />الجرعة التَّالیة من الدَّواء المضاد للتجلط، ثم استمر في الجرعات التالیة كالمعتاد.<br />- تغییر العلاج بالأدویة الأخرى المضادة للتجلط التي تحتوي على مضادات فیتامین &quot;ك&quot;<br />:&trade; (مثل وارفارین) إلى عقار بیكسابان<br />توقف عن تناول الدَّواء الذي یحتوي على مضادات فیتامین &quot;ك&quot;، وبعد ذلك یحتاج طبیبك إلى<br />.&trade; إجراء قیاسات وفحوصات للدم وسیقوم بإخبارك بوقت بدء تناوُل عقار بیكسابان<br />إلى العلاج بالأدویة الأخرى المضادة للتجلط التي &trade; - تغییر العلاج من عقار بیكسابان<br />تحتوي على مضادات فیتامین &quot;ك&quot; (مثل وارفارین):<br />إذا أخبرك طبیبك أنھ یجب علیك تناول عقار یحتوي على مناھضات فیتامین &quot;ك&quot;، فاستمر<br />لمدة یومین على الأقل بعد تناوُل جرعتك الأولى من الدواء الذي &trade; في تناوُل عقار بیكسابان<br />یحتوي على مناھضات فیتامین &quot;ك&quot;. یحتاج طبیبك إلى إجراء قیاسات وفحوصات للدم<br />.&trade; وسیقوم بإخبارك بالوقت المناسب للتَّوقف عن تناوُل عقار بیكسابان<br />في حالة المرضى الذین یخضعون لتقویم نظم القلب:<br />إذا كانت ھناك حاجة إلى إعادة تنظیم نبضات القلب غیر الطبیعیة عن طریق إجراء یسمى<br />في الأوقات التي یحددھا طبیبك ، لمنع تكون &trade; تقویم نظم القلب، یتم تناول عقار بیكسابان<br />الجلطات في الأوعیة الدمویة في الدماغ والأوعیة الدمویة الأخرى في الجسم.<br />:&trade; إذا تناولت كمیة أكثر مما یجب من عقار بیكسابان<br />أكثر من تلك الجرعة التي تم &trade; أخبر طبیبك على الفور، إذا تناولت جرعة من عقار بیكسابان<br />وصفھا طبیبك . اصطحب معك عبوة الدواء، حتى إذا لم یكن بھا أیة أقراص متبقیة.<br />أكثر من الجرعة الموصى بھا، فقد یُؤدي ذلك إلى &trade; إذا تناولت كمیة من عقار بیكسابان<br />زیادة خطر تعرضك للنزیف. وفي حالة الإصابة بنزیف، فقد یتطلب الأمر إجراء عملیة<br />. (Xa) جراحیة أو نقل دم أو استخدام علاجات أخرى تقوم بعكس نشاط مضاد العامل العاشر<br />:&trade; إذا نسیت تناوُل عقار بیكسابان<br />- قم بتناول الجرعة بمجرد تذكُّرك لھا.<br />في الموعد المعتاد. &trade; - تناول الجرعة التَّالیة من عقار بیكسابان<br />- ثم استمر في تناول الجرعات كالمعتاد.<br />إذا لم تكن متأكدًا مما یجب القیام بھ أو نسیت تناول أكثر من جرعة واحدة، استشر طبیبك أو<br />الصیدلي أو الممرض(ة) المتابع(ة) لحالتك.</p><p>إذا توقفت عن تناوُل عقار بیكسابان<br />دون التَّحدث إلى طبیبك أولًا؛ لأن نسبة خطورة &trade; لا تتوقف عن تناوُل عقار بیكسابان<br />حدوث تجلط في الدَّم قد تكون أكبر إذا توقفت عن تناوُل العلاج في وقت مبكر جدًا.<br />إذا كانت لدیك أیة أسئلة إضافیة حول استخدام ھذا الدَّواء، فاستشر طبیبك أو الصیدلي أو<br />الممرض(ة) المتابعة(ة) لحالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبب ھذا الدواء، مثلھ مثل كافة الأدویة، آثارًا جانبیة، على الرغم من عدم حدوثھا لجمیع<br />لعلاج ثلاث حالات طبیة مختلفة. قد تختلف الآثار &trade; المرضى. یمكن إعطاء عقار بیكسابان<br />الجانبیة المعروفة ومعدل تكرارھا في كل حالة من ھذه الحالات الطبیة المدرجة بشكل<br />ھو &trade; منفصل أدناه. بالنسبة لھذه الحالات، الأثر الجانبي الأكثر شیوعًا لعقار بیكسابان<br />حدوث نزیف قد یكون مُھددًا للحیاة ویستدعي العنایة الطبیة الفوریة.<br />لمنع تكوُّن الجلطات بعد &trade; تُعَد الآثار الجانبیة التَّالیة معروفة إذا كنت تتناول عقار بیكسابان<br />إجراء جراحات استبدال مفصل الحوض أو الركبة<br />آثار جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰ مرضى):<br />- نزیف یشمل: &bull; كدمات وتورم.<br />- غثیان (شعور بالإعیاء)<br />آثار جانبیة غیر شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰ مریض)<br />- انخفاض عدد الصفائح الدَّمویة في الدم (مما قد یُؤثر على التَّجلط).<br />- نزیف:<br />&bull; حدوث نزیف عقب إجراء جراحة بما في ذلك تكدُّم وتورُّم أو تسرُّب الدم أو السوائل من<br />الجرح/الشق الناتج عن الجراحة (إفرازات الجرح) أو موضع الحقن<br />&bull; نزیف في المعدة أو في الأمعاء &bull; نزیف من المستقیم &bull; نزیف بالفم &bull; نزیف من<br />المھبل.<br />- انخفاض ضغط الدم الذي قد یجعلك تشعر بالإغماء أو سرعة ضربات القلب.<br />- قد تظھر اختبارات الدم ما یلي:<br />&bull; اضطرابات بوظائف الكبد.<br />&bull; ارتفاع في بعض إنزیمات الكبد.<br />&bull; ارتفاع نسبة البیلیروبین، أحد نواتج تكسر كرات الدم الحمراء، مما قد یسبب اصفرار<br />البشرة والعینین.<br />- طفح جلدي.<br />آثار جانبیة نادرة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱٫۰۰۰ مریض)<br />- تفاعلات حساسیة (فرط الحساسیة) قد تسبب: تورم بالوجھ أو الشفتین أو الفم أو اللسان<br />و/أو الحلق وصعوبة في التنفس. اتصل بطبیبك على الفور، إذا عانیت من أي من ھذه<br />الأعراض.<br />- نزیف:<br />&bull; في العضلات &bull; في العینین &bull; من اللثة والدم في البصاق عند السعال &bull; من المستقیم<br />- تساقط الشعر.<br />آثار جانبیة غیر معروفة (لا یمكن تقدیر معدل تكرارھا من واقع البیانات المتاحة)<br />نزیف:<br />&bull; نزیف بالمخ أو بالعمود الفقري. &bull; في الرئتین أو الحلق &bull; في الفم<br />&bull; في المنطقة الموجودة خلف تجویف البطن &bull; من البواسیر<br />&bull; تظھر الاختبارات وجود دم في البراز أو في البول.<br />- طفح جلدي.<br />لمنع تكوُّن الجلطات &trade; تُعَد الآثار الجانبیة التَّالیة معروفة إذا كنت تتناول عقار بیكسابان<br />الدَّمویة بالقلب في المرضى الذین یُعانون من عدم انتظام ضربات القلب ووجود عامل خطر<br />إضافي واحد على الأقل.<br />آثار جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰ مرضى):<br />- نزیف یشمل: &bull; في العینین &bull; في المعدة أو في الامعاء &bull; من المستقیم<br />&bull; نزول دم مع البول &bull; من الأنف &bull; من اللثة &bull; كدمات وتورم.<br />- فقر الدَّم (أنیمیا) والذي قد یُسبب شعورًا بالإرھاق أو شحوبًا باللون.<br />- انخفاض ضغط الدم الذي قد یجعلك تشعر بالإغماء أو سرعة ضربات القلب.<br />- غثیان (شعور بالإعیاء)<br />.(GGT) - قد تظھر اختبارات الدم ارتفاع مستوى إنزیم ناقلة الجاما جلوتامایل<br />آثار جانبیة غیر شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰ مریض)<br />- نزیف:<br />&bull; نزیف بالمخ أو بالعمود الفقري.<br />&bull; نزیف بالفم أو وجود دم في البصاق عند السُّعال.<br />&bull; نزیف في البطن أو من المھبل.<br />&bull; وجود دم أحمر/فاتح اللون في البراز.<br />&bull; حدوث نزیف عقب إجراء جراحة بما في ذلك تكدُّم وتورُّم أو تسرُّب الدم أو السوائل من<br />الجرح/الشق الناتج عن الجراحة (إفرازات الجرح) أو موضع الحقن أو نزیف من البواسیر.<br />&bull; تظھر الاختبارات وجود دم في البراز أو في البول.<br />- انخفاض عدد الصفائح الدَّمویة في الدم (مما قد یُؤثر على التَّجلط).<br />- قد تظھر اختبارات الدم ما یلي:<br />&bull; اضطرابات بوظائف الكبد. &bull; ارتفاع في بعض إنزیمات الكبد.<br />&bull; ارتفاع نسبة البیلیروبین، أحد نواتج تكسر كرات الدم الحمراء، مما قد یسبب اصفرار<br />البشرة والعینین.<br />- طفح جلدي.<br />- حكة.<br />- تساقط الشعر.<br />- تفاعلات حساسیة (فرط الحساسیة) قد تسبب: تورم بالوجھ أو الشفتین أو الفم أو اللسان<br />و/أو الحلق وصعوبة في التنفس. اتصل بطبیبك على الفور، إذا عانیت من أي من ھذه<br />الأعراض.<br />آثار جانبیة نادرة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱٫۰۰۰ مریض)<br />- نزیف:<br />&bull; في الرئتین أو الحلق &bull; في المنطقة الموجودة خلف تجویف البطن &bull; في العضلات.<br />لعلاج أو لمنع إعادة &trade; تُعَد الآثار الجانبیة التَّالیة معروفة إذا كنت تتناول عقار بیكسابان<br />تكوُّن الجلطات الدَّمویة في أوردة الساق والأوعیة الدمویة بالرئة.<br />آثار جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰ مرضى):<br />- نزیف و یشمل :<br />&bull; من الأنف &bull; من اللثة &bull; دم في البول أو تكدم وتورم.<br />&bull; نزیف في المعدة أو في الأمعاء &bull; نزیف من المستقیم &bull; نزیف بالفم &bull; نزیف من<br />المھبل.<br />- فقر الدَّم (أنیمیا) والذي قد یُسبب شعورًا بالإرھاق أو شحوب لون البشرة.<br />- انخفاض عدد الصفائح الدَّمویة في الدم (مما قد یُؤثر على التَّجلط).<br />- غثیان (شعور بالإعیاء). - طفح جلدي.<br />قد تظھر اختبارات الدم ما یلي:<br />.(ALT) أو ناقلة الأمین الألانینیة (GGT) &bull; ارتفاع مستوى إنزیم ناقلة الجاما جلوتامایل<br />آثار جانبیة غیر شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰ مریض)<br />- انخفاض ضغط الدَّم الذي قد یجعلك تشعر بالإغماء أو تسارع نبضات القلب.<br />- نزیف یشمل : &bull; بالعینین &bull; بالفم &bull; وجود دم في البصاق عند السُّعال.<br />&bull; وجود دم فاتح اللون/أحمر في البراز. &bull; وجود دم في البراز أو في البول.<br />&bull; حدوث نزیف عقب إجراء أى جراحة بما في ذلك تكدُّم وتورُّم، تسرُّب الدم أو السوائل من<br />الجرح/الفتحة الناتجة عن الجراحة (إفرازات الجرح) أو موضع الحقن أو نزیف من<br />البواسیر<br />&bull; نزیف بالعضلات.<br />- حكة.<br />- تساقط الشعر.<br />- تفاعلات حساسیة (فرط الحساسیة) قد تسبب: تورم بالوجھ أو الشفتین أو الفم أو اللسان<br />و/أو الحلق وصعوبة في التنفس. اتصل بطبیبك على الفور إذا عانیت من أي من ھذه<br />الأعراض.<br />- قد تُظھر اختبارات الدم نتائج غیر طبیعیة بوظائف الكبد (زیادة في بعض إنزیمات الكبد).<br />&bull; ارتفاع نسبة البیلیروبین، أحد نواتج تكسیر كریات الدم الحمراء، مما قد یسبب اصفرارًا<br />البشرة والعینین.<br />آثار جانبیة نادرة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱,۰۰۰ مریض):<br />نزیف:<br />&bull; في المخ أو العمود الفقري. &bull; في الرئتین.<br />آثار جانبیة غیر معروفة (لا یمكن تقدیر معدل تكرارھا من واقع البیانات المتاحة)<br />نزیف: &bull; بالبطن أو في المنطقة الموجودة خلف تجویف البطن.<br />الإبلاغ عن الآثار الجانبیة<br />إذا أُصبت بأیة آثار جانبیة، فتحدَّث إلى طبیبك أو الصیدلي أو الممرض(ة) المتابع(ة)<br />لحالتك. ویشمل ذلك أيّ آثار جانبیة مُحتملة غیر مُدرجة في ھذه النَّشرة. كما یمكنك الإبلاغ<br />عن الآثار الجانبیة بشكل مباشر (انظر التفاصیل الواردة أدناه). یمكنك المساعدة بالإبلاغ<br />عن الآثار الجانبیة في توفیر المزید من المعلومات حول أمان استخدام ھذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُحفظ بعیدًا عن مُتناوَل و مرأى الأطفال.<br />م. &ordm; یحفظ في درجة حرارة لا تزید عن ۳۰<br />لا تستعمل ھذا الدَّواء بعد تاریخ انتھاء الصلاحیة المدون على العبوة والشریط بعد كلمة<br />.&quot;EXP&quot;<br />لا تتخلص من الأدویة عن طریق إلقائھا في میاه الصرف أو مع المخلفات المنزلیة. استشر<br />الصیدلي الخاص بك عن كیفیة التَّخلص من الأدویة التي لم تَعُد تستخدمھا. سوف تُساعد ھذه<br />الإجراءات في الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة ھي أبیكسابان.<br />۲٫٥ ملجم یحتوي كل قرص مغلف على ۲٫٥ ملجم أبیكسابان. &trade; بیكسابان<br />٥ ملجم یحتوي كل قرص مغلف على ٥ ملجم أبیكسابان. &trade; بیكسابان<br />&bull; المكونات الأخرى ھي:<br />لب القرص: لاكتوز لا مائي، سلیلوز فائق التَّبلور، كروسكارمیلوز الصودیوم، لوریل<br />كبریتات الصودیوم، ستیرات الماغنسیوم.<br />غلاف القرص : ھیدروكسي بروبیل میثیل السلیلوز ، مونوھیدرات اللاكتوز ، ثاني أكسید<br />التیتانیوم ، التریستین وأكسید الحدید الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما ھي محتویات العبوة ؟&trade; ما ھو شكل عقار بیكسابان<br />۲.٥ ملجم أقراص ھي أقراص مغلفة، دائریة ، لونھا وردي محفور على أحد &trade; بیكسابان<br />.&lsquo;&lsquo;JP&lsquo;&rsquo; وعلى الجانب الآخر &lsquo;&lsquo;BB&lsquo;&rsquo; جانبیھا<br />٥ ملجم أقراص ھي أقراص مغلفة، دائریة ، لونھا وردي محفور على أحد &trade; بیكسابان<br />.&lsquo;&lsquo;JP&lsquo;&rsquo; وعلى الجانب الآخر &lsquo;&lsquo;BC&lsquo;&rsquo; جانبیھا<br />۲٫٥ ملجم أقراص مغلفة متوفرة في علبة بھا ۲۰ قرص و ٦۰ قرص. &trade; بیكسابان<br />٥ ملجم أقراص مغلفة متوفرة في علبة بھا ٦۰ قرص. &trade; بیكسابان<br />قد لا یتم تسویق جمیع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسویق و المصنع:<br />شركة مصنع جمجوم للأدویة،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />۲۳٤۰-۲۳٥٦- تحویلة: ۲۳۱۷<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02-09-2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pexapan (Apixaban) 5mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pexapan 5mg Film Coated Tablets
Each film coated tablet contains 5 mg of Apixaban.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.
Pink, oval film coated tablets, debossed with "BC" on one side and "JP" on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.</p><p>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age &ge; 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class &ge; II).</p><p>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)</u> The recommended dose of apixaban is 5 mg taken orally twice daily.</p><p>Dose reduction</p><p>The recommended dose of apixaban is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age &ge; 80 years, body weight &le; 60 kg, or serum creatinine &ge; 1.5 mg/dL (133 micromole/L).</p><p>Therapy should be continued long-term.</p><p>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)</p><p>The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily. As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilisation).</p><p>The recommended dose of apixaban for the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily. When prevention of recurrent DVT and PE is indicated, the 2.5 mg twice daily dose should be initiated following completion of 6 months of treatment with apixaban 5 mg twice daily or with another anticoagulant, as indicated in Table 1 below (see also section 5.1)</p><p>Table 1:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dosing schedule</p></td><td style="vertical-align:top"><p>Maximum daily dose</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Treatment of DVT or PE</p></td><td style="vertical-align:top"><p>10 mg twice daily for the first 7 days</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>followed by 5 mg twice daily</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of recurrent DVT and/or PE following completion of 6 months of treatment for DVT or PE</p></td><td style="vertical-align:top"><p>2.5 mg twice daily</p></td><td style="vertical-align:top"><p>5 mg</p></td></tr></tbody></table><p>The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).</p><p><u>Missed dose</u></p><p>If a dose is missed, the patient should take Apixaban immediately and then continue with twice daily intake as before.</p><p><u>Switching</u></p><p>Switching treatment from parenteral anticoagulants to Apixaban (and vice versa) can be done at the next scheduled dose (see section 4.5). These medicinal products should not be administered simultaneously.</p><p>Switching from vitamin K antagonist (VKA) therapy to Apixaban</p><p>When converting patients from vitamin K antagonist (VKA) therapy to Apixaban, warfarin or other VKA therapy should be discontinued and Apixaban started when the international normalised ratio (INR) is &lt; 2.</p><p>Switching from Apixaban to VKA therapy</p><p>When converting patients from Apixaban to VKA therapy, administration of Apixaban should be continued for at least 2 days after beginning VKA therapy. After 2 days of coadministration of Apixaban with VKA therapy, an INR should be obtained prior to the next scheduled dose of Apixaban.</p><p>Coadministration of Apixaban and VKA therapy should be continued until the INR is &ge; 2.</p><p><em><u>Renal impairment</u></em></p><p><em>&nbsp;</em>In patients with mild or moderate renal impairment, the following recommendations apply:</p><p>-&nbsp; for the prevention of VTE in elective hip or knee replacement surgery (VTEp), for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), no dose adjustment is necessary (see section 5.2).</p><p>-&nbsp;&nbsp; for the prevention of stroke and systemic embolism in patients with NVAF and serum creatinine &ge; 1.5 mg/dL (133 micromole/L) associated with age &ge; 80 years or body weight &le; 60 kg, a dose reduction is</p><p>necessary and described above. In the absence of other criteria for dose reduction (age, body weight), no dose adjustment is necessary (see section 5.2).</p><p>In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see sections 4.4 and 5.2):</p><p>-&nbsp;&nbsp; for the prevention of VTE in elective hip or knee replacement surgery (VTEp), for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) apixaban is to be used with caution;</p><p>-&nbsp;&nbsp; for the prevention of stroke and systemic embolism in patients with NVAF, patients should receive the lower dose of apixaban 2.5 mg twice daily.</p><p>In patients with creatinine clearance &lt; 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.4 and 5.2).</p><p><em><u>Hepatic impairment</u></em></p><p>Apixaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).</p><p>It is not recommended in patients with severe hepatic impairment (see sections 4.4. and 5.2).</p><p>It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B). No dose adjustment is required in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).</p><p>Patients with elevated liver enzymes alanine aminotransferase (ALT)/aspartate aminotransferase (AST)</p><p>&gt;2 x ULN or total bilirubin &ge; 1.5 x ULN were excluded in clinical trials. Therefore Apixaban should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating Apixaban, liver function testing should be performed.</p><p><em><u>Body weight</u></em></p><p>VTEp and VTEt - No dose adjustment required (see sections 4.4 and 5.2).</p><p>NVAF - No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2).</p><p>Gender</p><p>No dose adjustment required (see section 5.2). Elderly</p><p>VTEp and VTEt &ndash; No dose adjustment required (see sections 4.4 and 5.2).</p><p>NVAF &ndash; No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2).</p><p><em><u>Patients undergoing catheter ablation (NVAF)</u></em></p><p>Patients can continue apixaban use while undergoing catheter ablation (see sections 4.3, 4.4 and 4.5).</p><p><em><u>Patients undergoing cardioversion</u></em></p><p>Apixaban can be initiated or continued in NVAF patients who may require cardioversion.</p><p>For patients not previously treated with anticoagulants, exclusion of left atrial thrombus using an image guided approach (e.g. transesophogeal echocardiography (TEE) or computed tomographic scan (CT)) prior to cardioversion should be considered, in accordance with established medical guidelines.</p><p>For patients initiating treatment with apixaban, 5 mg should be given twice daily for at least 2.5 days (5 single doses) before cardioversion to ensure adequate anticoagulation (see section 5.1). The dosing regimen should be reduced to 2.5 mg apixaban given twice daily for at least 2.5 days (5 single doses) if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment).</p><p>If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily. The dosing regimen should be reduced to a 5 mg loading dose followed by 2.5 mg twice daily if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment). The administration of the loading dose should be given at least 2 hours before cardioversion (see section 5.1).</p><p>For all patients undergoing cardioversion, confirmation should be sought prior to cardioversion that the patient has taken apixaban as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.</p><p><em><u>Patients with NVAF and acute coronary syndrome (ACS) and/or percutaneous coronary intervention</u> <u>(PCI)</u></em></p><p>There is limited experience of treatment with apixaban at the recommended dose for NVAF patients when used in combination with antiplatelet agents in patients with ACS and/or undergoing PCI after haemostasis is achieved (see sections 4.4, 5.1).</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of Apixaban in children and adolescents below age 18 have not been established. No data are available.</p><p><em><u>Method of administration</u></em></p><p>Oral use</p><p>Apixaban should be swallowed with water, with or without food.</p><p>For patients who are unable to swallow whole tablets, Apixaban tablets may be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally (see section 5.2). Alternatively, Apixaban tablets may be crushed and suspended in 60 mL of water or D5W and immediately delivered through a nasogastric tube (see section 5.2).</p><p>Crushed Apixaban tablets are stable in water, D5W, apple juice, and apple puree for up to 4 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Active clinically significant bleeding.
•	Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 5.2).
•	Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
•	Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2), when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Haemorrhage risk</u></em></p><p>As with other anticoagulants, patients taking Apixaban are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Apixaban administration should be discontinued if severe haemorrhage occurs (see sections 4.8 and 4.9).</p><p>Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see section 5.1).</p><p>An agent to reverse the anti-factor Xa activity of apixaban is available.</p><p><em><u>Interaction with other medicinal products affecting haemostasis</u></em></p><p>Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).</p><p>The concomitant use of Apixaban with antiplatelet agents increases the risk of bleeding (see section 4.5).</p><p>Care is to be taken if patients are treated concomitantly with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.</p><p>Following surgery, other platelet aggregation inhibitors are not recommended concomitantly with Apixaban (see section 4.5).</p><p>In patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the potential risks should be made before combining this therapy with Apixaban.</p><p>In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.1%) use of concomitant dual antiplatelet therapy (see section 5.1).</p><p>A clinical trial enrolled patients with atrial fibrillation with ACS and/or undergoing PCI and a planned treatment period with a P2Y12 inhibitor, with or without ASA, and oral anticoagulant (either apixaban or VKA) for 6 months. Concomitant use of ASA increased the risk of ISTH (International Society on</p><p>Thrombosis and Hemostasis) major or CRNM (Clinically Relevant Non-Major) bleeding in apixaban- treated subjects from 16.4% per year to 33.1% per year (see section 5.1).</p><p>In a clinical trial of high-risk post acute coronary syndrome patients without atrial fibrillation, characterised by multiple cardiac and non-cardiac comorbidities, who received ASA or the combination of ASA and clopidogrel, a significant increase in risk of ISTH major bleeding was reported for apixaban (5.13% per year) compared to placebo (2.04% per year).</p><p><em><u>Use of thrombolytic agents for the treatment of acute ischemic stroke</u></em></p><p>There is very limited experience with the use of thrombolytic agents for the treatment of acute ischemic stroke in patients administered apixaban. (see section 4.5).</p><p><em><u>Patients with prosthetic heart valves</u></em></p><p>Safety and efficacy of Apixaban have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation. Therefore, the use of Apixaban is not recommended in this setting.</p><p><em><u>Patients with antiphospholipid syndrome</u></em></p><p>Direct acting Oral Anticoagulants (DOACs) including apixaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p><p><em><u>Surgery and invasive procedures</u></em></p><p>Apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding. This includes interventions for which the probability of clinically significant bleeding cannot be excluded or for which the risk of bleeding would be unacceptable.</p><p>Apixaban should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding. This includes interventions for which any bleeding that occurs is expected to be minimal, non-critical in its location or easily controlled.</p><p>If surgery or invasive procedures cannot be delayed, appropriate caution should be exercised, taking into consideration an increased risk of bleeding. This risk of bleeding should be weighed against the urgency of intervention.</p><p>Apixaban should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established (for cardioversion see section 4.2).</p><p>For patients undergoing catheter ablation for atrial fibrillation, Apixaban treatment does not need to be interrupted (see sections 4.2, 4.3 and 4.5).</p><p><em><u>Temporary discontinuation</u></em></p><p>Discontinuing anticoagulants, including Apixaban, for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of thrombosis. Lapses in therapy should be avoided and if anticoagulation with Apixaban must be temporarily discontinued for any reason, therapy should be restarted as soon as possible.</p><p>Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy</p><p>Apixaban is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of apixaban have not been established in these clinical situations.</p><p>Patients with active cancer</p><p>Efficacy and safety of apixaban in the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) in patients with active cancer have not been established.</p><p><em><u>Patients with renal impairment</u></em></p><p>Limited clinical data indicate that apixaban plasma concentrations are increased in patients with severe renal impairment (creatinine clearance 15-29 mL/min) which may lead to an increased bleeding risk. For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), apixaban is to be used with caution in patients with severe renal impairment (creatinine clearance 15-29 mL/min) (see sections 4.2 and 5.2).</p><p>For the prevention of stroke and systemic embolism in patients with NVAF, patients with severe renal impairment (creatinine clearance 15-29 mL/min), and patients with serum creatinine &ge; 1.5 mg/dL (133 micromole/L) associated with age &ge; 80 years or body weight &le; 60 kg should receive the lower dose of apixaban 2.5 mg twice daily (see section 4.2);</p><p>In patients with creatinine clearance &lt; 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.2 and 5.2).</p><p><em><u>Elderly patients</u></em></p><p>Increasing age may increase haemorrhagic risk (see section 5.2).</p><p>Also, the co-administration of Apixaban with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk.</p><p><em><u>Body weight</u></em></p><p>Low body weight (&lt; 60 kg) may increase haemorrhagic risk (see section 5.2). Patients with hepatic impairment</p><p>Apixaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).</p><p>It is not recommended in patients with severe hepatic impairment (see section 5.2).</p><p>It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B) (see sections 4.2 and 5.2).</p><p>Patients with elevated liver enzymes ALT/AST &gt; 2 x ULN or total bilirubin &ge; 1.5 x ULN were excluded in clinical trials. Therefore Apixaban should be used cautiously in this population (see section 5.2). Prior to initiating Apixaban, liver function testing should be performed.</p><p>Interaction with inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp)</p><p>The use of Apixaban is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir). These medicinal products may increase apixaban exposure by 2-fold (see section 4.5) or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment).</p><p>Interaction with inducers of both CYP3A4 and P-gp</p><p>The concomitant use of Apixaban with strong CYP3A4 and P-gp inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort) may lead to a ~50% reduction in apixaban exposure. In a clinical study in atrial fibrillation patients, diminished efficacy and a higher risk of bleeding were observed with coadministration of apixaban with strong inducers of both CYP3A4 and P-gp compared with using apixaban alone.</p><p>In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp the following recommendations apply (see section 4.5):</p><p>-&nbsp;&nbsp; for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE, apixaban should be used with caution;</p><p>-&nbsp;&nbsp; for the treatment of DVT and treatment of PE, apixaban should not be used since efficacy may be compromised.</p><p><em><u>Laboratory parameters</u></em></p><p>Clotting tests [e.g., prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT)] are affected as expected by the mechanism of action of apixaban. Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability (see section 5.1).</p><p>Information about excipients</p><p>Apixaban contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Inhibitors of CYP3A4 and P-gp</u></em></p><p>Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inhibitor of both CYP3A4 and P-gp, led to a 2-fold increase in mean apixaban AUC and a 1.6-fold increase in mean apixaban Cmax.</p><p>The use of Apixaban is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see section 4.4).</p><p>Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (eg., amiodarone, clarithromycin, diltiazem, fluconazole, naproxen, quinidine, verapamil) are expected to increase apixaban plasma concentration to a lesser extent. No dose adjustment for apixaban is required when coadministered with agents that are not strong inhibitors of both CYP3A4 and P-gp. For example, diltiazem (360 mg once a day), considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4- fold increase in mean apixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively. Clarithromycin (500 mg, twice a day), an inhibitor of P-gp and a strong inhibitor of CYP3A4, led to a 1.6-fold and 1.3-fold increase in mean apixaban AUC and Cmax respectively.</p><p><em><u>Inducers of CYP3A4 and P-gp</u></em></p><p>Coadministration of apixaban with rifampicin, a strong inducer of both CYP3A4 and P-gp, led to an approximate 54% and 42% decrease in mean apixaban AUC and Cmax, respectively. The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine,</p><p>phenobarbital or St. John&#39;s Wort) may also lead to reduced apixaban plasma concentrations. No dose adjustment for apixaban is required during concomitant therapy with such medicinal products, however in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp apixaban should be used with caution for the prevention of VTE in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE.</p><p>Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp since efficacy may be compromised (see section 4.4).</p><p><em><u>Anticoagulants, platelet aggregation inhibitors, SSRIs/SNRIs and NSAIDs</u></em></p><p>Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated except under specific circumstances of switching anticoagulant therapy, when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation (see section 4.3).</p><p>After combined administration of enoxaparin (40 mg single dose) with apixaban (5 mg single dose), an additive effect on anti-Factor Xa activity was observed.</p><p>Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325 mg once a day.</p><p>Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel 75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.</p><p>Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively. Corresponding increases in clotting tests were observed for apixaban. No changes were observed in the effect of naproxen on arachidonic acid-induced platelet aggregation and no clinically relevant prolongation of bleeding time was observed after concomitant administration of apixaban and naproxen.</p><p>Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplatelet agents are coadministered with apixaban. Apixaban should be used with caution when coadministered with SSRIs/SNRIs, NSAIDs, ASA and/or P2Y12 inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).</p><p>There is limited experience of co-administration with other platelet aggregation inhibitors (such as GPIIb/IIIa receptor antagonists, dipyridamole, dextran or sulfinpyrazone) or thrombolytic agents. As such agents increase the bleeding risk, co-administration of these products with Apixaban is not recommended (see section 4.4).</p><p><em><u>Other concomitant therapies</u></em></p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10 mg with atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban. Following administration of the two medicinal products together, mean apixaban AUC and Cmax were 15% and 18% lower than when administered alone. The administration of apixaban 10 mg with famotidine 40 mg had no effect on apixaban AUC or Cmax.</p><p><em><u>Effect of apixaban on other medicinal products</u></em></p><p>In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 &gt; 45 &micro;M) and weak inhibitory effect on the activity of CYP2C19 (IC50 &gt; 20 &micro;M) at concentrations that are significantly greater than peak plasma concentrations observed in patients. Apixaban did not induce CYP1A2, CYP2B6, CYP3A4/5 at a concentration up to 20 &micro;M. Therefore, apixaban is not expected to alter the metabolic clearance of coadministered medicinal products that are metabolised by these enzymes. Apixaban is not a significant inhibitor of P-gp.</p><p>In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol.</p><p><em>Digoxin</em></p><p>Coadministration of apixaban (20 mg once a day) and digoxin (0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax. Therefore, apixaban does not inhibit P-gp mediated substrate transport.</p><p><em>Naproxen</em></p><p>Coadministration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, did not have any effect on the naproxen AUC or Cmax.</p><p><em>Atenolol</em></p><p>Coadministration of a single dose of apixaban (10 mg) and atenolol (100 mg), a common beta-blocker, did not alter the pharmacokinetics of atenolol.</p><p><em><u>Activated charcoal</u></em></p><p>Administration of activated charcoal reduces apixaban exposure (see section 4.9).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p>There are no data from the use of apixaban in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Apixaban is not recommended during pregnancy.</p><p><em><u>Breast-feeding</u></em></p><p>It is unknown whether apixaban or its metabolites are excreted in human milk. Available data in animals have shown excretion of apixaban in milk. In rat milk, a high milk to maternal plasma ratio (Cmax about 8, AUC about 30) was found, possibly due to active transport into the milk. A risk to newborns and infants cannot be excluded.</p><p>A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy.</p><p><em><u>Fertility</u></em></p><p>Studies in animals dosed with apixaban have shown no effect on fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apixaban has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Summary of the safety profile</u></em></p><p>The safety of apixaban has been investigated in 7 Phase III clinical studies including more than 21,000 patients: more than 5,000 patients in VTEp studies, more than 11,000 patients in NVAF studies and more than 4,000 patients in the VTE treatment (VTEt) studies, for an average total exposure of 20 days,</p><p>1.7 years and 221 days respectively (see section 5.1).</p><p>Common adverse reactions were haemorrhage, contusion, epistaxis, and haematoma (see Table 2 for adverse reaction profile and frequencies by indication).</p><p>In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced adverse reactions. The overall incidence of adverse reactions related to bleeding with apixaban was 10% in the apixaban vs enoxaparin studies.</p><p>In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in the apixaban vs warfarin study and 9.6% in the apixaban vs acetylsalicylic acid study. In the apixaban vs warfarin study the incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year. The incidence of ISTH major intraocular bleeding with apixaban was 0.18%/year.</p><p>In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6% in the apixaban vs enoxaparin/warfarin study and 13.3% in the apixaban vs placebo study (see section 5.1).</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to</p><p>&lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data) for VTEp, NVAF, and VTEt respectively.</p><p><strong>Table 2: Tabulated adverse reactions</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><strong>System organ class</strong></p></td><td colspan="" rowspan=""><p><strong>Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery (VTEp)</strong></p></td><td colspan="" rowspan=""><p><strong>Prevention of stroke and systemic embolism in adult patients with NVAF, with one or more risk factors (NVAF)</strong></p></td><td colspan="" rowspan=""><p><strong>Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTEt)</strong></p></td></tr><tr><td colspan="4" rowspan=""><p><em>Blood and lymphatic system disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Anaemia</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Thrombocytopenia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Immune system disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Hypersensitivity, allergic oedema and Anaphylaxis</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Pruritus</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon<sup>*</sup></p></td></tr><tr><td colspan="" rowspan=""><p>Angioedema</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Nervous system disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Brain haemorrhage<sup>&dagger;</sup></p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Rare</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Eye disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Eye haemorrhage (including conjunctival haemorrhage)</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Vascular disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Haemorrhage, haematoma</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Hypotension (including procedural hypotension)</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Intra-abdominal haemorrhage</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Epistaxis</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Haemoptysis</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Respiratory tract haemorrhage</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Rare</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Nausea</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Gastrointestinal haemorrhage</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Haemorrhoidal haemorrhage</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Mouth haemorrhage</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Haematochezia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Rectal haemorrhage, gingival bleeding</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Retroperitoneal haemorrhage</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Hepatobiliary disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Liver function test abnormal, asparate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Gamma-glutamyltransferase increased</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Alanine aminotransferase increased</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Skin rash</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Alopecia</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Erythema multiforme</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Cutaneous vasculitis</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Muscle haemorrhage</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Renal and urinary disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Haematuria</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td colspan="" rowspan=""><p>Abnormal vaginal haemorrhage, urogenital haemorrhage</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="4" rowspan=""><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td colspan="" rowspan=""><p>Application site bleeding</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Investigations</em></p></td></tr><tr><td colspan="" rowspan=""><p>Occult blood positive</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="4" rowspan=""><p><em>Injury, poisoning and procedural complications</em></p></td></tr><tr><td colspan="" rowspan=""><p>Contusion</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Post procedural haemorrhage (including post procedural haematoma, wound haemorrhage, vessel puncture site haematoma and catheter site haemorrhage), wound secretion, incision site haemorrhage (including incision site haematoma), operative haemorrhage</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Traumatic haemorrhage</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr></tbody></table><p><sup>*</sup>&nbsp;There were no occurrences of generalised pruritus in CV185057 (long term prevention of VTE)</p><p><sup>&dagger;&nbsp;</sup>The term &ldquo; Brain haemorrhage&rdquo; encompasses all intracranial or intraspinal haemorrhages (i.e., haemorrhagic stroke or putamen, cerebellar, intraventricular, or subdural haemorrhages).</p><p>The use of apixaban may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in post- haemorrhagic anaemia. The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding (see sections 4.4 and 5.1).</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store</p><p><strong>&nbsp;</strong>&bull;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222,</p><p>Ext: 2317-2356-2340.</p><p>Reporting hotline: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>&bull;&nbsp; Other GCC States:</p><p>&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose of apixaban may result in a higher risk of bleeding. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. The initiation of appropriate treatment, e.g., surgical haemostasis, the transfusion of fresh frozen plasma or the administration of a reversal agent for factor Xa inhibitors should be considered.</p><p>In controlled clinical trials, orally-administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily (bid) for 7 days or 50 mg once daily (od) for 3 days) had no clinically relevant adverse effects.</p><p>In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20 mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively, and had no impact on Cmax. Mean half-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3 hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours after apixaban. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.</p><p>For situations when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, a reversal agent for factor Xa inhibitors is available (see section 4.4). Administration of prothrombin complex concentrates (PCCs) or recombinant factor VIIa may also be considered. Reversal of Apixaban pharmacodynamic effects, as demonstrated by changes in the thrombin generation assay, was evident at the end of infusion and reached baseline values within 4 hours after the start of a 4-factor PCC 30 minute infusion in healthy subjects. However, there is no clinical experience with the use of 4-factor PCC products to reverse bleeding in individuals who have received Apixaban. Currently there is no experience with the use of recombinant factor VIIa in individuals receiving apixaban. Re-dosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding.</p><p>Depending on local availability, a consultation of a coagulation expert should be considered in case of major bleedings.</p><p>Haemodialysis decreased apixaban AUC by 14% in subjects with end-stage renal disease (ESRD), when a single dose of apixaban 5 mg was administered orally. Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF02</p><p>Mechanism of action</p><p>Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development. Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis.</p><p>Pharmacodynamic effects</p><p>The pharmacodynamic effects of apixaban are reflective of the mechanism of action (Factor Xa inhibition). As a result of Factor Xa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability. They are not recommended to assess the pharmacodynamic effects of apixaban. In the thrombin generation assay, apixaban reduced endogenous thrombin potential, a measure of thrombin generation in human plasma.</p><p>Apixaban also demonstrates anti-Factor Xa activity as evident by reduction in Factor Xa enzyme activity in multiple commercial anti-Factor Xa kits, however results differ across kits. Data from clinical studies are only available for the Rotachrom<sup>&reg;</sup>&nbsp;Heparin chromogenic assay. Anti-Factor Xa activity exhibits a close direct linear relationship with apixaban plasma concentration, reaching maximum values at the time of apixaban peak plasma concentrations. The relationship between apixaban plasma concentration and anti-Factor Xa activity is approximately linear over a wide dose range of apixaban.</p><p>Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity. In non-valvular atrial fibrillation patients taking apixaban for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels. In patients taking apixaban for the treatment of DVT and PE or prevention of recurrent DVT and PE, the results demonstrate a less than 2.2-fold fluctuation in peak-to-trough levels.</p><p><strong>Table 3: Predicted apixaban steady-state exposure and anti-Factor Xa activity</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apix. C<sub>max</sub>&nbsp;(ng/mL)</strong></p></td><td colspan="" rowspan=""><p><strong>Apix. C<sub>min</sub>&nbsp;(ng/mL)</strong></p></td><td colspan="" rowspan=""><p><strong>Apix. anti- Factor Xa activity max</strong></p><p><strong>(IU/mL)</strong></p></td><td colspan="" rowspan=""><p><strong>Apix. anti- Factor Xa activity min</strong></p><p><strong>(IU/mL)</strong></p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="4" rowspan=""><p>Median [5th, 95th percentile]</p></td></tr><tr><td colspan="5" rowspan=""><p><em>Prevention of stroke and systemic embolism: NVAF</em></p></td></tr><tr><td colspan="" rowspan=""><p>2.5 mg twice daily*</p></td><td colspan="" rowspan=""><p>123 [69, 221]</p></td><td colspan="" rowspan=""><p>79 [34, 162]</p></td><td colspan="" rowspan=""><p>1.8 [1.0, 3.3]</p></td><td colspan="" rowspan=""><p>1.2 [0.51, 2.4]</p></td></tr><tr><td colspan="" rowspan=""><p>5 mg twice daily</p></td><td colspan="" rowspan=""><p>171 [91, 321]</p></td><td colspan="" rowspan=""><p>103 [41, 230]</p></td><td colspan="" rowspan=""><p>2.6 [1.4, 4.8]</p></td><td colspan="" rowspan=""><p>1.5 [0.61, 3.4]</p></td></tr><tr><td colspan="5" rowspan=""><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)</em></p></td></tr><tr><td colspan="" rowspan=""><p>2.5 mg twice daily</p></td><td colspan="" rowspan=""><p>67 [30, 153]</p></td><td colspan="" rowspan=""><p>32 [11, 90]</p></td><td colspan="" rowspan=""><p>1.0 [0.46, 2.5]</p></td><td colspan="" rowspan=""><p>0.49 [0.17, 1.4]</p></td></tr><tr><td colspan="" rowspan=""><p>5 mg twice daily</p></td><td colspan="" rowspan=""><p>132 [59, 302]</p></td><td colspan="" rowspan=""><p>63 [22, 177]</p></td><td colspan="" rowspan=""><p>2.1 [0.91, 5.2]</p></td><td colspan="" rowspan=""><p>1.0 [0.33, 2.9]</p></td></tr><tr><td colspan="" rowspan=""><p>10 mg twice daily</p></td><td colspan="" rowspan=""><p>251 [111, 572]</p></td><td colspan="" rowspan=""><p>120 [41, 335]</p></td><td colspan="" rowspan=""><p>4.2 [1.8, 10.8]</p></td><td colspan="" rowspan=""><p>1.9 [0.64, 5.8]</p></td></tr></tbody></table><p>* Dose adjusted population based on 2 of 3 dose reduction criteria in the ARISTOTLE study.</p><p>Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.</p><p>Clinical efficacy and safety</p><p><em>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)</em></p><p>A total of 23,799 patients were randomised in the clinical program (ARISTOTLE: apixaban versus warfarin, AVERROES: apixaban versus ASA) including 11,927 randomised to apixaban. The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and one or more additional risk factors, such as:</p><p>&bull; prior stroke or transient ischaemic attack (TIA)</p><p>&bull; age &ge; 75 years</p><p>&bull; hypertension</p><p>&bull; diabetes mellitus</p><p>&bull; symptomatic heart failure (NYHA Class &ge; II)</p><p><em>ARISTOTLE study</em></p><p>In the ARISTOTLE study a total of 18,201 patients were randomised to double-blind treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [4.7%], see section 4.2) or warfarin (target INR range 2.0-3.0), patients were exposed to study active substance for a mean of 20 months. The mean age was 69.1 years, the mean CHADS<sub>2</sub>&nbsp;score was 2.1 and 18.9% of patients had prior stroke or TIA.</p><p>In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 4) compared with warfarin.</p><p><strong>Table 4: Efficacy outcomes in patients with atrial fibrillation in the ARISTOTLE study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apixaban N=9,120</strong></p><p><strong>n (%/yr)</strong></p></td><td colspan="" rowspan=""><p><strong>Warfarin N=9,081</strong></p><p><strong>n (%/yr)</strong></p></td><td colspan="" rowspan=""><p><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p><p><strong>p-value</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Stroke or systemic embolism</p></td><td colspan="" rowspan=""><p>212 (1.27)</p></td><td colspan="" rowspan=""><p>265 (1.60)</p></td><td colspan="" rowspan=""><p>0.79 (0.66, 0.95)</p></td><td colspan="" rowspan=""><p>0.0114</p></td></tr><tr><td colspan="" rowspan=""><p>Stroke</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Ischaemic or unspecified</p></td><td colspan="" rowspan=""><p>162 (0.97)</p></td><td colspan="" rowspan=""><p>175 (1.05)</p></td><td colspan="" rowspan=""><p>0.92 (0.74, 1.13)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Haemorrhagic</p></td><td colspan="" rowspan=""><p>40 (0.24)</p></td><td colspan="" rowspan=""><p>78 (0.47)</p></td><td colspan="" rowspan=""><p>0.51 (0.35, 0.75)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Systemic embolism</p></td><td colspan="" rowspan=""><p>15 (0.09)</p></td><td colspan="" rowspan=""><p>17 (0.10)</p></td><td colspan="" rowspan=""><p>0.87 (0.44, 1.75)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr></tbody></table><p>For patients randomised to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%.</p><p>Apixaban showed a reduction of stroke and systemic embolism compared to warfarin across the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% CI, 0.38, 1.40).</p><p>Key secondary endpoints of major bleeding and all cause death were tested in a pre- specified hierarchical testing strategy to control the overall type 1 error in the trial. Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 5). With improving monitoring of INR the observed benefits of apixaban compared to warfarin regarding all cause death diminish.</p><p><strong>Table 5: Secondary endpoints in patients with atrial fibrillation in the ARISTOTLE study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apixaban N = 9,088</strong></p><p><strong>n (%/year)</strong></p></td><td colspan="" rowspan=""><p><strong>Warfarin N = 9,052</strong></p><p><strong>n (%/year)</strong></p></td><td colspan="" rowspan=""><p><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="" rowspan=""><p><strong>p-value</strong></p></td></tr><tr><td colspan="5" rowspan=""><p>Bleeding outcomes</p></td></tr><tr><td colspan="" rowspan=""><p>Major*</p></td><td colspan="" rowspan=""><p>327 (2.13)</p></td><td colspan="" rowspan=""><p>462 (3.09)</p></td><td colspan="" rowspan=""><p>0.69 (0.60, 0.80)</p></td><td colspan="" rowspan=""><p>&lt; 0.0001</p></td></tr><tr><td colspan="" rowspan=""><p>Fatal</p></td><td colspan="" rowspan=""><p>10 (0.06)</p></td><td colspan="" rowspan=""><p>37 (0.24)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Intracranial</p></td><td colspan="" rowspan=""><p>52 (0.33)</p></td><td colspan="" rowspan=""><p>122 (0.80)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Major + CRNM<sup>&dagger;</sup></p></td><td colspan="" rowspan=""><p>613 (4.07)</p></td><td colspan="" rowspan=""><p>877 (6.01)</p></td><td colspan="" rowspan=""><p>0.68 (0.61, 0.75)</p></td><td colspan="" rowspan=""><p>&lt; 0.0001</p></td></tr><tr><td colspan="" rowspan=""><p>All</p></td><td colspan="" rowspan=""><p>2356 (18.1)</p></td><td colspan="" rowspan=""><p>3060 (25.8)</p></td><td colspan="" rowspan=""><p>0.71 (0.68, 0.75)</p></td><td colspan="" rowspan=""><p>&lt; 0.0001</p></td></tr><tr><td colspan="5" rowspan=""><p>Other endpoints</p></td></tr><tr><td colspan="" rowspan=""><p>All-cause death</p></td><td colspan="" rowspan=""><p>603 (3.52)</p></td><td colspan="" rowspan=""><p>669 (3.94)</p></td><td colspan="" rowspan=""><p>0.89 (0.80, 1.00)</p></td><td colspan="" rowspan=""><p>0.0465</p></td></tr><tr><td colspan="" rowspan=""><p>Myocardial infarction</p></td><td colspan="" rowspan=""><p>90 (0.53)</p></td><td colspan="" rowspan=""><p>102 (0.61)</p></td><td colspan="" rowspan=""><p>0.88 (0.66, 1.17)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr></tbody></table><p>* Major bleeding defined per International Society on Thrombosis and Haemostasis (ISTH) criteria.</p><p>&dagger; Clinically Relevant Non-Major</p><p>The overall discontinuation rate due to adverse reactions was 1.8% for apixaban and 2.6% for warfarin in the ARISTOTLE study.</p><p>The efficacy results for prespecified subgroups, including CHADS<sub>2</sub>&nbsp;score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the primary efficacy results for the overall population studied in the trial.</p><p>The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin.</p><p>The major bleeding results for prespecified subgroups including CHADS<sub>2</sub>&nbsp;score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the results for the overall population studied in the trial.</p><p><em>AVERROES study</em></p><p>In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomised to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA. ASA was given at a once daily dose of 81 mg (64%), 162 (26.9%), 243 (2.1%), or 324 mg (6.6%) at the discretion of the investigator. Patients were exposed to study active substance for a mean of 14 months. The mean age was 69.9 years, the mean CHADS<sub>2</sub>&nbsp;score was 2.0 and 13.6% of patients had prior stroke or TIA.</p><p>Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%), and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%).</p><p>AVERROES was stopped early based on a recommendation by the independent Data Monitoring Committee due to clear evidence of reduction of stroke and systemic embolism with an acceptable safety profile.</p><p>The overall discontinuation rate due to adverse reactions was 1.5% for apixaban and 1.3% for ASA in the AVERROES study.</p><p>In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 6) compared to ASA.</p><p><strong>Table 6: Key efficacy outcomes in patients with atrial fibrillation in the AVERROES study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apixaban</strong></p><p><strong>N = 2,807</strong></p><p><strong>n (%/year)</strong></p></td><td colspan="" rowspan=""><p><strong>ASA</strong></p><p><strong>N = 2,791</strong></p><p><strong>n (%/year)</strong></p></td><td colspan="" rowspan=""><p><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p><p><strong>p-value</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Stroke or systemic embolism*</p></td><td colspan="" rowspan=""><p>51 (1.62)</p></td><td colspan="" rowspan=""><p>113 (3.63)</p></td><td colspan="" rowspan=""><p>0.45 (0.32, 0.62)</p></td><td colspan="" rowspan=""><p>&lt; 0.0001</p></td></tr><tr><td colspan="" rowspan=""><p>Stroke</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Ischaemic or unspecified</p></td><td colspan="" rowspan=""><p>43 (1.37)</p></td><td colspan="" rowspan=""><p>97 (3.11)</p></td><td colspan="" rowspan=""><p>0.44 (0.31, 0.63)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Haemorrhagic</p></td><td colspan="" rowspan=""><p>6 (0.19)</p></td><td colspan="" rowspan=""><p>9 (0.28)</p></td><td colspan="" rowspan=""><p>0.67 (0.24, 1.88)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Systemic embolism</p></td><td colspan="" rowspan=""><p>2 (0.06)</p></td><td colspan="" rowspan=""><p>13 (0.41)</p></td><td colspan="" rowspan=""><p>0.15 (0.03, 0.68)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Stroke, systemic embolism, MI, or vascular death<strong>*</strong><sup>&dagger;</sup></p></td><td colspan="" rowspan=""><p>132 (4.21)</p></td><td colspan="" rowspan=""><p>197 (6.35)</p></td><td colspan="" rowspan=""><p>0.66 (0.53, 0.83)</p></td><td colspan="" rowspan=""><p>0.003</p></td></tr><tr><td colspan="" rowspan=""><p>Myocardial infarction</p></td><td colspan="" rowspan=""><p>24 (0.76)</p></td><td colspan="" rowspan=""><p>28 (0.89)</p></td><td colspan="" rowspan=""><p>0.86 (0.50, 1.48)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Vascular death</p></td><td colspan="" rowspan=""><p>84 (2.65)</p></td><td colspan="" rowspan=""><p>96 (3.03)</p></td><td colspan="" rowspan=""><p>0.87 (0.65, 1.17)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>All-cause death<sup>&dagger;</sup></p></td><td colspan="" rowspan=""><p>111 (3.51)</p></td><td colspan="" rowspan=""><p>140 (4.42)</p></td><td colspan="" rowspan=""><p>0.79 (0.62, 1.02)</p></td><td colspan="" rowspan=""><p>0.068</p></td></tr></tbody></table><p>* Assessed by sequential testing strategy designed to control the overall type I error in the trial.</p><p>&dagger; Secondary endpoint.</p><p>There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 7).</p><p><strong>Table 7: Bleeding events in patients with atrial fibrillation in the AVERROES study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apixaban N = 2,798</strong></p><p><strong>N (%/year)</strong></p></td><td colspan="" rowspan=""><p><strong>ASA N = 2,780</strong></p><p><strong>n (%/year)</strong></p></td><td colspan="" rowspan=""><p><strong>Hazard ratio (95%CI)</strong></p></td><td colspan="" rowspan=""><p><strong>p-value</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Major*</p></td><td colspan="" rowspan=""><p>45 (1.41)</p></td><td colspan="" rowspan=""><p>29 (0.92)</p></td><td colspan="" rowspan=""><p>1.54 (0.96, 2.45)</p></td><td colspan="" rowspan=""><p>0.0716</p></td></tr><tr><td colspan="" rowspan=""><p>Fatal, n</p></td><td colspan="" rowspan=""><p>5 (0.16)</p></td><td colspan="" rowspan=""><p>5 (0.16)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Intracranial, n</p></td><td colspan="" rowspan=""><p>11 (0.34)</p></td><td colspan="" rowspan=""><p>11 (0.35)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Major + CRNM&dagger;</p></td><td colspan="" rowspan=""><p>140 (4.46)</p></td><td colspan="" rowspan=""><p>101 (3.24)</p></td><td colspan="" rowspan=""><p>1.38 (1.07, 1.78)</p></td><td colspan="" rowspan=""><p>0.0144</p></td></tr><tr><td colspan="" rowspan=""><p>All</p></td><td colspan="" rowspan=""><p>325 (10.85)</p></td><td colspan="" rowspan=""><p>250 (8.32)</p></td><td colspan="" rowspan=""><p>1.30 (1.10, 1.53)</p></td><td colspan="" rowspan=""><p>0.0017</p></td></tr></tbody></table><p>*Major bleeding defined per International Society on Thrombosis and Haemostasis (ISTH) criteria.</p><p>&dagger; Clinically Relevant Non-Major</p><p><em>NVAF patients with ACS and/or undergoing PCI</em></p><p>AUGUSTUS, an open-label, randomised, controlled, 2 by 2 factorial design trial, enrolled 4614 patients with NVAF who had ACS (43%) and/or underwent PCI (56%). All patients received background therapy with a P2Y12 inhibitor (clopidogrel: 90.3%) prescribed per local standard of care.</p><p>Patients were randomised up to 14 days after the ACS and/or PCI to either apixaban 5 mg twice daily (2.5 mg twice daily if two or more of the dose-reduction criteria were met; 4.2% received lower dose) or VKA and to either ASA (81 mg once daily) or placebo. The mean age was 69.9 years, 94% of patients randomised had a CHA<sub>2</sub>DS<sub>2</sub>- VASc score &gt; 2, and 47% had a HAS-BLED score &gt; 3. For patients randomised to VKA, the proportion of time in therapeutic range (TTR) (INR 2-3) was 56%, with 32% of time below TTR and 12% above TTR.</p><p>The primary objective of AUGUSTUS was to assess safety, with a primary endpoint of ISTH major or CRNM bleeding. In the apixaban versus VKA comparison, the primary safety endpoint of ISTH major or CRNM bleeding at month 6 occurred in 241 (10.5%), and 332 (14.7%) patients in the apixaban arm and in the VKA arm respectively (HR=0.69, 95% CI: 0.58, 0.82; 2-sided p&lt;0.0001 for non inferiority and p&lt;0.0001 for superiority). For VKA, additional analyses using subgroups by TTR showed that the highest rate of bleeding was associated with the lowest quartile of TTR. The rate of bleeding was similar between apixaban and the highest quartile of TTR.</p><p>In the ASA versus placebo comparison, the primary safety endpoint of ISTH major or CRNM bleeding at month 6 occurred in 367 (16.1%), and 204 (9.0%) patients in the ASA arm and in the placebo arm respectively (HR=1.88, 95% CI: 1.58, 2.23; two- sided p&lt;0.0001).</p><p>Specifically, in apixaban-treated patients, major or CRNM bleeding occurred in 157 (13.7%), and 84 (7.4%) patients in the ASA arm and in the placebo arm respectively. In VKA-treated patients, major or CRNM bleeding occurred in 208 (18.5%), and 122 (10.8%) patients in the ASA arm and in the placebo arm respectively.</p><p>Other treatment effects were evaluated as a secondary objective of the study, with composite endpoints.</p><p>In the apixaban versus VKA comparison, the composite endpoint of death or re- hospitalisation occurred in 541 (23.5%) and 632 (27.4%) patients in the apixaban and in the VKA arm, respectively. The composite endpoint of death or ischemic event (stroke, myocardial infarction, stent thrombosis or urgent revascularisation) occurred in 170 (7.4%), and 182 (7.9%) patients in the apixaban and in the VKA arm, respectively.</p><p>In the ASA versus placebo comparison, the composite endpoint of death or re- hospitalisation occurred in 604 (26.2%) and 569 (24.7%) patients in the ASA and in the placebo arm, respectively. The composite endpoint of death or ischemic event (stroke, myocardial infarction, stent thrombosis or urgent revascularisation) occurred in 163 (7.1%), and 189 (8.2%) patients in the ASA and in the placebo arm, respectively.</p><p><em>Patients undergoing cardioversion</em></p><p>EMANATE, an open-label, multi-center study, enrolled 1500 patients who were either oral anticoagulant na&iuml;ve or pre-treated less than 48 hours, and scheduled for cardioversion for NVAF. Patients were randomised 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular events. Electrical and/or pharmacologic cardioversion was conducted after at least 5 doses of 5 mg twice daily apixaban (or 2.5 mg twice daily in selected patients (see section 4.2)) or at least 2 hours after a 10 mg loading dose (or a 5 mg loading dose in selected patients (see section 4.2)) if earlier cardioversion was required. In the apixaban group, 342 patients received a loading dose (331 patients received the 10 mg dose and 11 patients received the 5 mg dose).</p><p>There were no strokes (0%) in the apixaban group (n= 753) and 6 (0.80%) strokes in the heparin and/or VKA group (n = 747; RR 0.00, 95% CI 0.00, 0.64). All-cause death occurred in 2 patients (0.27%) in the apixaban group and 1 patient (0.13%) in the heparin and/or VKA group. No systemic embolism events were reported.</p><p>Major bleeding and CRNM bleeding events occurred in 3 (0.41%) and 11 (1.50%) patients, respectively, in the apixaban group, compared to 6 (0.83%) and 13 (1.80%) patients in the heparin and/or VKA group.</p><p>This exploratory study showed comparable efficacy and safety between apixaban and heparin and/or VKA treatment groups in the setting of cardioversion.</p><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)</em></p><p>The clinical program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY- EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT). Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE. All the key safety and efficacy endpoints were adjudicated by an independent blinded committee.</p><p><em>AMPLIFY study</em></p><p>In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR &ge; 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.</p><p>The mean age was 56.9 years and 89.8% of randomised patients had unprovoked VTE events.</p><p>For patients randomised to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9. Apixaban showed a reduction in recurrent symptomatic VTE or VTE- related death across the different levels of center TTR; within the highest quartile of TTR according to center, the relative risk for apixaban vs enoxaparin/warfarin was 0.79 (95% CI, 0.39, 1.61).</p><p>In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 8).</p><p><strong>Table 8: Efficacy results in the AMPLIFY study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apixaban N=2,609 n (%)</strong></p></td><td colspan="" rowspan=""><p><strong>Enoxaparin/ Warfarin N=2,635</strong></p><p><strong>n (%)</strong></p></td><td colspan="" rowspan=""><p><strong>Relative risk (95% CI)</strong></p></td></tr><tr><td colspan="" rowspan=""><p>VTE or VTE-related death</p></td><td colspan="" rowspan=""><p>59 (2.3)</p></td><td colspan="" rowspan=""><p>71 (2.7)</p></td><td colspan="" rowspan=""><p>0.84 (0.60, 1.18)*</p></td></tr><tr><td colspan="" rowspan=""><p>DVT</p></td><td colspan="" rowspan=""><p>20 (0.7)</p></td><td colspan="" rowspan=""><p>33 (1.2)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>PE</p></td><td colspan="" rowspan=""><p>27 (1.0)</p></td><td colspan="" rowspan=""><p>23 (0.9)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>VTE-related death</p></td><td colspan="" rowspan=""><p>12 (0.4)</p></td><td colspan="" rowspan=""><p>15 (0.6)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>VTE or all-cause death</p></td><td colspan="" rowspan=""><p>84 (3.2)</p></td><td colspan="" rowspan=""><p>104 (4.0)</p></td><td colspan="" rowspan=""><p>0.82 (0.61, 1.08)</p></td></tr><tr><td colspan="" rowspan=""><p>VTE or CV-related death</p></td><td colspan="" rowspan=""><p>61 (2.3)</p></td><td colspan="" rowspan=""><p>77 (2.9)</p></td><td colspan="" rowspan=""><p>0.80 (0.57, 1.11)</p></td></tr><tr><td colspan="" rowspan=""><p>VTE, VTE-related death, or major bleeding</p></td><td colspan="" rowspan=""><p>73 (2.8)</p></td><td colspan="" rowspan=""><p>118 (4.5)</p></td><td colspan="" rowspan=""><p>0.62 (0.47, 0.83)</p></td></tr></tbody></table><p>* Noninferior compared to enoxaparin/warfarin (p-value &lt;0.0001)</p><p>Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE [Relative Risk 0.9; 95% CI (0.5, 1.6)] or DVT [Relative Risk 0.8; 95% CI (0.5, 1.3)]. Efficacy across subgroups, including age, gender, body mass index (BMI), renal function, extent of index PE, location of DVT thrombus, and prior parenteral heparin use was generally consistent.</p><p>The primary safety endpoint was major bleeding. In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value &lt;0.0001] (see Table 9).</p><p><strong>Table 9: Bleeding results in the AMPLIFY study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apixaban</strong></p><p><strong>N=2,676</strong></p><p><strong>n (%)</strong></p></td><td colspan="" rowspan=""><p><strong>Enoxaparin/ Warfarin</strong></p><p><strong>N=2,689</strong></p><p><strong>n (%)</strong></p></td><td colspan="" rowspan=""><p><strong>Relative risk</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Major</p></td><td colspan="" rowspan=""><p>15 (0.6)</p></td><td colspan="" rowspan=""><p>49 (1.8)</p></td><td colspan="" rowspan=""><p>0.31 (0.17, 0.55)</p></td></tr><tr><td colspan="" rowspan=""><p>Major + CRNM</p></td><td colspan="" rowspan=""><p>115 (4.3)</p></td><td colspan="" rowspan=""><p>261 (9.7)</p></td><td colspan="" rowspan=""><p>0.44 (0.36, 0.55)</p></td></tr><tr><td colspan="" rowspan=""><p>Minor</p></td><td colspan="" rowspan=""><p>313 (11.7)</p></td><td colspan="" rowspan=""><p>505 (18.8)</p></td><td colspan="" rowspan=""><p>0.62 (0.54, 0.70)</p></td></tr><tr><td colspan="" rowspan=""><p>All</p></td><td colspan="" rowspan=""><p>402 (15.0)</p></td><td colspan="" rowspan=""><p>676 (25.1)</p></td><td colspan="" rowspan=""><p>0.59 (0.53, 0.66)</p></td></tr></tbody></table><p>The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban group as compared to the enoxaparin/warfarin group. Adjudicated ISTH major gastrointestinal bleeding occurred in 6 (0.2%) apixaban- treated patients and 17 (0.6%) enoxaparin/warfarin-treated patients.</p><p><em>AMPLIFY-EXT study</em></p><p>In the AMPLIFY-EXT study a total of 2,482 patients were randomised to treatment with apixaban 2.5 mg twice daily orally, apixaban 5 mg twice daily orally, or placebo for 12 months after completing 6 to 12 months of initial anticoagulant treatment. Of these, 836 patients (33.7%) participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study. The mean age was 56.7 years and 91.7% of randomised patients had unprovoked VTE events.</p><p>In the study, both doses of apixaban were statistically superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE) or all-cause death (see Table 10).</p><p><strong>Table 10: Efficacy results in the AMPLIFY-EXT study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="3"><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apixaban</strong></p></td><td colspan="" rowspan=""><p><strong>Apixaban</strong></p></td><td colspan="" rowspan=""><p><strong>Placebo</strong></p></td><td colspan="2" rowspan=""><p><strong>Relative risk (95% CI)</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>2.5 mg</strong></p><p><strong>(N=840)</strong></p></td><td colspan="" rowspan=""><p><strong>5.0 mg</strong></p><p><strong>(N=813)</strong></p></td><td colspan="" rowspan="" style="vertical-align:bottom"><p><strong>(N=829)</strong></p></td><td colspan="" rowspan=""><p><strong>Apix 2.5 mg vs. placebo</strong></p></td><td colspan="" rowspan=""><p><strong>Apix 5.0 mg vs. placebo</strong></p></td></tr><tr><td colspan="3" rowspan=""><p>n (%)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Recurrent VTE or all- cause death</p></td><td colspan="" rowspan=""><p>19 (2.3)</p></td><td colspan="" rowspan=""><p>14 (1.7)</p></td><td colspan="" rowspan=""><p>77 (9.3)</p></td><td colspan="" rowspan=""><p>0.24</p><p>(0.15, 0.40)<sup>&yen;</sup></p></td><td colspan="" rowspan=""><p>0.19</p><p>(0.11, 0.33)<sup>&yen;</sup></p></td></tr><tr><td colspan="" rowspan=""><p>DVT*</p></td><td colspan="" rowspan=""><p>6 (0.7)</p></td><td colspan="" rowspan=""><p>7 (0.9)</p></td><td colspan="" rowspan=""><p>53 (6.4)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>PE*</p></td><td colspan="" rowspan=""><p>7 (0.8)</p></td><td colspan="" rowspan=""><p>4 (0.5)</p></td><td colspan="" rowspan=""><p>13 (1.6)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>All-cause death</p></td><td colspan="" rowspan=""><p>6 (0.7)</p></td><td colspan="" rowspan=""><p>3 (0.4)</p></td><td colspan="" rowspan=""><p>11 (1.3)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Recurrent VTE or VTE-related death</p></td><td colspan="" rowspan=""><p>14 (1.7)</p></td><td colspan="" rowspan=""><p>14 (1.7)</p></td><td colspan="" rowspan=""><p>73 (8.8)</p></td><td colspan="" rowspan=""><p>0.19</p><p>(0.11, 0.33)</p></td><td colspan="" rowspan=""><p>0.20</p><p>(0.11, 0.34)</p></td></tr><tr><td colspan="" rowspan=""><p>Recurrent VTE or CV-related death</p></td><td colspan="" rowspan=""><p>14 (1.7)</p></td><td colspan="" rowspan=""><p>14 (1.7)</p></td><td colspan="" rowspan=""><p>76 (9.2)</p></td><td colspan="" rowspan=""><p>0.18</p><p>(0.10, 0.32)</p></td><td colspan="" rowspan=""><p>0.19</p><p>(0.11, 0.33)</p></td></tr><tr><td colspan="" rowspan=""><p>Nonfatal DVT<sup>&dagger;</sup></p></td><td colspan="" rowspan=""><p>6 (0.7)</p></td><td colspan="" rowspan=""><p>8 (1.0)</p></td><td colspan="" rowspan=""><p>53 (6.4)</p></td><td colspan="" rowspan=""><p>0.11</p><p>(0.05, 0.26)</p></td><td colspan="" rowspan=""><p>0.15</p><p>(0.07, 0.32)</p></td></tr><tr><td colspan="" rowspan=""><p>Nonfatal PE<sup>&dagger;</sup></p></td><td colspan="" rowspan=""><p>8 (1.0)</p></td><td colspan="" rowspan=""><p>4 (0.5)</p></td><td colspan="" rowspan=""><p>15 (1.8)</p></td><td colspan="" rowspan=""><p>0.51</p><p>(0.22, 1.21)</p></td><td colspan="" rowspan=""><p>0.27</p><p>(0.09, 0.80)</p></td></tr><tr><td colspan="" rowspan=""><p>VTE-related death</p></td><td colspan="" rowspan=""><p>2 (0.2)</p></td><td colspan="" rowspan=""><p>3 (0.4)</p></td><td colspan="" rowspan=""><p>7 (0.8)</p></td><td colspan="" rowspan=""><p>0.28</p><p>(0.06, 1.37)</p></td><td colspan="" rowspan=""><p>0.45</p><p>(0.12, 1.71)</p></td></tr></tbody></table><p><sup>&yen;&nbsp;</sup>p-value &lt; 0.0001</p><p>* For patients with more than one event contributing to the composite endpoint, only the first event was reported (e.g. if a subject experienced both a DVT and then a PE, only the DVT was reported)</p><p>&dagger; Individual subjects could experience more than one event and be represented in both classifications</p><p>Apixaban efficacy for prevention of a recurrence of a VTE was maintained across subgroups, including age, gender, BMI, and renal function.</p><p>The primary safety endpoint was major bleeding during the treatment period. In the study, the incidence in major bleeding for both apixaban doses was not statistically different from placebo. There was no statistically significant difference in the incidence of major + CRNM, minor, and all bleeding between the apixaban 2.5 mg twice daily and placebo treatment groups (see Table 11).</p><p><strong>Table 11: Bleeding results in the AMPLIFY-EXT study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="3"><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Apixaban</strong></p></td><td colspan="" rowspan=""><p><strong>Apixaban</strong></p></td><td colspan="" rowspan=""><p><strong>Placebo</strong></p></td><td colspan="2" rowspan=""><p><strong>Relative risk (95% CI)</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>2.5 mg</strong></p><p>(N=840)</p></td><td colspan="" rowspan=""><p><strong>5.0 mg</strong></p><p>(N=811)</p></td><td colspan="" rowspan="" style="vertical-align:bottom"><p>(N=826)</p></td><td colspan="" rowspan=""><p><strong>Apix 2.5 mg</strong>&nbsp;vs. placebo</p></td><td colspan="" rowspan=""><p><strong>Apix 5.0 mg</strong>&nbsp;vs. placebo</p></td></tr><tr><td colspan="3" rowspan=""><p>n (%)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Major</p></td><td colspan="" rowspan=""><p>2 (0.2)</p></td><td colspan="" rowspan=""><p>1 (0.1)</p></td><td colspan="" rowspan=""><p>4 (0.5)</p></td><td colspan="" rowspan=""><p>0.49</p><p>(0.09, 2.64)</p></td><td colspan="" rowspan=""><p>0.25</p><p>(0.03, 2.24)</p></td></tr><tr><td colspan="" rowspan=""><p>Major + CRNM</p></td><td colspan="" rowspan=""><p>27 (3.2)</p></td><td colspan="" rowspan=""><p>35 (4.3)</p></td><td colspan="" rowspan=""><p>22 (2.7)</p></td><td colspan="" rowspan=""><p>1.20</p><p>(0.69, 2.10)</p></td><td colspan="" rowspan=""><p>1.62</p><p>(0.96, 2.73)</p></td></tr><tr><td colspan="" rowspan=""><p>Minor</p></td><td colspan="" rowspan=""><p>75 (8.9)</p></td><td colspan="" rowspan=""><p>98 (12.1)</p></td><td colspan="" rowspan=""><p>58 (7.0)</p></td><td colspan="" rowspan=""><p>1.26</p><p>(0.91, 1.75)</p></td><td colspan="" rowspan=""><p>1.70</p><p>(1.25, 2.31)</p></td></tr><tr><td colspan="" rowspan=""><p>All</p></td><td colspan="" rowspan=""><p>94 (11.2)</p></td><td colspan="" rowspan=""><p>121 (14.9)</p></td><td colspan="" rowspan=""><p>74 (9.0)</p></td><td colspan="" rowspan=""><p>1.24</p><p>(0.93, 1.65)</p></td><td colspan="" rowspan=""><p>1.65</p><p>(1.26, 2.16)</p></td></tr></tbody></table><p>Adjudicated ISTH major gastrointestinal bleeding occurred in 1 (0.1%) apixaban- treated patient at the 5 mg twice daily dose, no patients at the 2.5 mg twice daily dose, and 1 (0.1%) placebo-treated patient.</p><p>Paediatric population</p><p>There is no authorised paediatric indication (see section 4.2).</p><p><em>Prevention of VTE in paediatric patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma (ALL, LL)</em></p><p>In the PREVAPIX-ALL study, a total of 512 patients age &ge;1 to &lt;18 with newly diagnosed ALL or LL, undergoing induction chemotherapy including asparaginase via an indwelling central venous access device, were randomised 1:1 to open-label thromboprophylaxis with apixaban or standard of care (with no systemic anticoagulation). Apixaban was administered according to a fixed-dose, body weight- tiered regimen designed to produce exposures comparable to those seen in adults who received 2.5 mg twice daily (see Table 12). Apixaban was provided as a 2.5 mg tablet, 0.5 mg tablet, or 0.4 mg/mL oral solution. The median duration of exposure in the apixaban arm was 25 days.</p><p><strong>Table 12: Apixaban dosing in the PREVAPIX-ALL study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><strong>Weight Range</strong></p></td><td colspan="" rowspan=""><p><strong>Dose schedule</strong></p></td></tr><tr><td colspan="" rowspan=""><p>6 to &lt;10.5 kg</p></td><td colspan="" rowspan=""><p>0.5 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>10.5 to &lt;18 kg</p></td><td colspan="" rowspan=""><p>1 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>18 to &lt;25 kg</p></td><td colspan="" rowspan=""><p>1.5 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>25 to &lt;35 kg</p></td><td colspan="" rowspan=""><p>2 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>&ge;35 kg</p></td><td colspan="" rowspan=""><p>2.5 mg twice daily</p></td></tr></tbody></table><p>The primary efficacy endpoint was a composite of adjudicated symptomatic and asymptomatic non-fatal deep vein thrombosis, pulmonary embolism, cerebral venous sinus thrombosis, and venous thromboembolism-related death. The incidence of the primary efficacy endpoint was 31 (12.1%) in the apixaban arm versus 45 (17.6%) in the standard of care arm. The relative risk reduction did not achieve significance.</p><p>Safety endpoints were adjudicated according to ISTH criteria. The primary safety endpoint, major bleeding, occurred in 0.8% of patients in each treatment arm. CRNM bleeding occurred in 11 patients (4.3%) in the apixaban arm and 3 patients (1.2%) in the standard of care arm. The most common CRNM bleeding event contributing to the treatment difference was mild to moderate intensity epistaxis. Minor bleeding events occurred in 37 patients in the apixaban arm (14.5%) and 20 patients (7.8%) in the standard of care arm.</p><p><em>Prevention of thromboembolism (TE) in paediatric patients with congenital or acquired heart disease</em></p><p>SAXOPHONE was a randomised 2:1 open-label, multi-center comparative study of patients 28 days to &lt;18 years of age with congenital or acquired heart disease who require anticoagulation. Patients received either apixaban or standard of care thromboprophylaxis with a vitamin K antagonist or low molecular weight heparin. Apixaban was administered according to a fixed-dose, body weight-tiered regimen designed to produce exposures comparable to those seen in adults who received a dose of 5 mg twice daily (see Table 13). Apixaban was provided as a 5 mg tablet, 0.5 mg tablet, or 0.4 mg/mL oral solution. The mean duration of exposure in the apixaban arm was 331 days.</p><p><strong>Table 13: Apixaban dosing in the SAXOPHONE study</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><strong>Weight Range</strong></p></td><td colspan="" rowspan=""><p><strong>Dose schedule</strong></p></td></tr><tr><td colspan="" rowspan=""><p>6 to &lt;9 kg</p></td><td colspan="" rowspan=""><p>1 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>9 to &lt;12 kg</p></td><td colspan="" rowspan=""><p>1.5 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>12 to &lt;18 kg</p></td><td colspan="" rowspan=""><p>2 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>18 to &lt;25 kg</p></td><td colspan="" rowspan=""><p>3 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>25 to &lt;35 kg</p></td><td colspan="" rowspan=""><p>4 mg twice daily</p></td></tr><tr><td colspan="" rowspan=""><p>&ge;35 kg</p></td><td colspan="" rowspan=""><p>5 mg twice daily</p></td></tr></tbody></table><p>The primary safety endpoint, a composite of adjudicated ISTH defined major and CRNM bleeding, occurred in 1 (0.8%) of 126 patients in the apixaban arm and 3 (4.8%) of 62 patients in the standard of care arm. The secondary safety endpoints of adjudicated major, CRNM, and all bleeding events were similar in incidence across the two treatment arms. The secondary safety endpoint of drug discontinuation due to adverse event, intolerability, or bleeding was reported in 7 (5.6%) subjects in the apixaban arm and 1 (1.6%) subject in the standard of care arm. No patients in either treatment arm experienced a thromboembolic event. There were no deaths in either treatment arm.</p><p>This study was prospectively designed for descriptive efficacy and safety because of the expected low incidence of TE and bleeding events in this population. Due to the observed low incidence of TE in this study a definitive risk benefit assessment could not be established.</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies for the treatment of venous thromboembolism with Apixaban in one or more subsets of the paediatric population (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Apixaban is rapidly absorbed with maximum concentrations (Cmax) appearing 3 to 4 hours after tablet intake. Intake with food does not affect apixaban AUC or Cmax at the 10 mg dose. Apixaban can be taken with or without food.</p><p>Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg. At doses &ge; 25 mg apixaban displays dissolution limited absorption with decreased bioavailability. Apixaban exposure parameters exhibit low to moderate variability reflected by a within- subject and inter-subject variability of ~20% CV and ~30% CV, respectively.</p><p>Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets suspended in 30 mL of water, exposure was comparable to exposure after oral administration of 2 whole 5 mg tablets. Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the Cmax and AUC were 21% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets. The reduction in exposure is not considered clinically relevant.</p><p>Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose.</p><p>Given the predictable, dose-proportional pharmacokinetic profile of apixaban, the bioavailability results from the conducted studies are applicable to lower apixaban doses.</p><p><u>Distribution</u></p><p>Plasma protein binding in humans is approximately 87%. The volume of distribution (Vss) is approximately 21 litres.</p><p>Biotransformation and elimination</p><p>Apixaban has multiple routes of elimination. Of the administered apixaban dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces. Renal excretion of apixaban accounts for approximately 27% of total clearance. Additional contributions from biliary and direct intestinal excretion were observed in clinical and nonclinical studies, respectively.</p><p>Apixaban has a total clearance of about 3.3 L/h and a half-life of approximately 12 hours.</p><p>O-demethylation and hydroxylation at the 3-oxopiperidinyl moiety are the major sites of biotransformation. Apixaban is metabolised mainly via CYP3A4/5 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. Unchanged apixaban is the major drug-related component in human plasma with no active circulating metabolites present. Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).</p><p><u>Renal impairment</u></p><p>There was no impact of impaired renal function on peak concentration of apixaban. There was an increase in apixaban exposure correlated to decrease in renal function, as assessed via measured creatinine clearance. In individuals with mild (creatinine clearance 51-80 mL/min), moderate (creatinine clearance 30-50 mL/min) and severe (creatinine clearance 15-29 mL/min) renal impairment, apixaban plasma concentrations (AUC) were increased 16, 29, and 44% respectively, compared to individuals with normal creatinine clearance. Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity.</p><p>In subjects with end-stage renal disease (ESRD), the AUC of apixaban was increased by 36% when a single dose of apixaban 5 mg was administered immediately after haemodialysis, compared to that seen in subjects with normal renal function. Haemodialysis, started two hours after administration of a single dose of apixaban 5 mg, decreased apixaban AUC by 14% in these ESRD subjects, corresponding to an apixaban dialysis clearance of 18 mL/min. Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.</p><p><u>Hepatic impairment</u></p><p>In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment, Child-Pugh B score 7 (n = 6) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment. Changes in anti-Factor Xa activity and INR were comparable between subjects with mild to moderate hepatic impairment and healthy subjects.</p><p><u>Elderly</u></p><p>Elderly patients (above 65 years) exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 32% higher and no difference in Cmax.</p><p><u>Gender</u></p><p>Exposure to apixaban was approximately 18% higher in females than in males. Ethnic origin and race</p><p>The results across phase I studies showed no discernible difference in apixaban pharmacokinetics between White/Caucasian, Asian and Black/African American subjects. Findings from a population pharmacokinetic analysis in patients who received apixaban were generally consistent with the phase I results.</p><p><u>Body weight</u></p><p>Compared to apixaban exposure in subjects with body weight of 65 to 85 kg, body weight &gt; 120 kg was associated with approximately 30% lower exposure and body weight &lt; 50 kg was associated with approximately 30% higher exposure.</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>The pharmacokinetic /pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 &ndash; 50 mg). The relationship between apixaban plasma concentration and anti- Factor Xa activity was best described by a linear model. The PK/PD relationship observed in patients was consistent with that established in healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, fertility and embryo-foetal development and juvenile toxicity.</p><p>The major observed effects in the repeated dose toxicity studies were those related to the pharmacodynamic action of apixaban on blood coagulation parameters. In the toxicity studies little to no increase of bleeding tendency was found. However, since this may be due to a lower sensitivity of the non-clinical species compared to humans, this result should be interpreted with caution when extrapolating to humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Anhydrous</p><p>Microcrystalline Cellulose</p><p>Croscarmellose Sodium</p><p>Sodium Lauryl Sulfate</p><p>Magnesium Stearate</p><p>Opadry Pink</p><p>Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg; C.</p><p>Keep out the sight and reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pexapan 5mg Film Coated Tablets are packed as 60 tablets (in Alu-Alu Blister).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267
Jeddah 21442, Saudi Arabia. Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apr 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>